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Chapter 7

MENSTRUAL DISORDERS IN
ADOLESCENT FEMALES

Donald E Greydanus*, MD, Hatim A Omar, MD,
Artemis K Tsitsika, MD,PhD andDilip R Patel, MD

Michigan State University College of Human Medicine,
MSU/Kalamazoo Center for Medical Studies, Kalamazoo, Michigan,
United States of America, Adolescent Medicine andYoung Parent
Programs, Kentucky Clinic, University of Kentucky, Lexington,
Kentucky, United States of America andAdolescent Health Unit, Second
Department of Pediatrics, University of Athens-Greece and« P & A
Kyriakou » Children's Hospital, Athens, Greece
Onset of menstruation (i.e., menarche) is a determining event
of the adolescent female signifying the progress of puberty, which in
the majority of cases is visibly initiated with thelarche (onset of
breast development or breast buds). Menarche usually occurs during
the earlier time of the second decade of life and ends with
menopause, typically in the 5th decade of life. The adolescent can
Correspondence: Donald E Greydanus, MD, Professor of Pediatrics and Human
Development, Michigan State University College of Human Medicine, Pediatrics
Program Director, MSU/Kalamazoo Center for Medical Studies, 1000 Oakland
Drive, Kalamazoo, MI 49008-1284 United States, E-mail:
Greydanus@kcms.mus.edu
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present with a wide variety of menstrual dilemmas and disorders
which will be discussed in this chapter.

INTRODUCTION
The onset of menstruation (i.e., menarche) is a seminal event of the
adolescent female signifying the progress of puberty, which in the
majority of cases is visibly initiated with thelarche (onset of breast
development or breast buds). Menarche usually occurs during the earlier
time of the second decade of life and ends with menopause, typically in the
5th decade of life(1). The adolescent can present with a wide variety of
menstrual dilemmas and disorders. After an introduction which
includes a synopsis of menstrual physiology, many of these menstrual
conditions arc considered in this discussion, including dysfunctional
uterine bleeding (DUB), amenorrhea (primary and secondary) and
dysmenorrhea (primary and secondary) (1,2).

PHYSIOLOGY OF MENSTRUATION
Puberty is the period involving the development of secondary sexual
characteristics and the attainment of sexual reproduction capacity (3).
The transition of puberty occurs usually between 10 and 16+ years of age
and is impacted by several hormones which affect the cellular and
glandular components of the reproductive system, leading to the
anatomical changes of puberty. Thelarche occurs on average between 10
to 10.5 years of age with a range of 8 to 13 years in Caucasian females
and earlier in African-American females (4,5). Menarche occurs on
average at 12.0 years of age in African-American females and 12.6 for
Caucasian females; a wide range is noted from 9 to 16 years (4,5). The
development of regular ovulatory menstrual cycles may take 1 to 5 years
after menarche as the hypothalamic-pituitary-ovarian (HPO) axis
continues to mature (1,6). Table 1 provides definitions for important
menstrual disorders.
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Table 1. Menstrual disorders definitions*

1. Normal adult menstrual cycle:
a. Mean interval of 28 days (±7 days)
b. Duration of menses of 4 days (±2-3 days)
c . Median blood loss is about 30 ml per month ( with the upper
limit of normal defined as 60-80 ml per month)
2. Amenorrhea : Absence of menses; can be Primary or Secondary
(absence of three consequent menstrual cycles, after regular periods
have been established)
3. Oligomenorhea: Infrequent. irregular bleeding at >45-day intervals
4. Menorrhagia: Prolonged (>7 days) or excessive (>80 ml) uterine
bleeding occurring at regular intervals
5. Metrorrhagia: Uterine bleeding occurring at irregular but frequent
intervals, the amount being variable
6. Menometrorrhagia: Prolonged uterine bleeding occurring at
irregular intervals
7. Hypermenorrhea: Synonymous with meno1rhagia
8. Polymenorrhea: Uterine bleeding occurring at regular intervals of
<21 days
9. Dysfunctional uterine bleeding: abnormal (different from that
patient's normal) uterine bleeding that is unrelated to any anatomic
lesion

• Reprinted, with permission from: Greydanus DE. Breast and gynecological
disorders. In: Hofmann AD, Greydanus DE, eds. Adolescent medicine, 3rd
ed. Stamford, CT: Appleton Lauge, 1997:547.
Physical changes in breast and pubic hair development as well as in
somatic growth present clear evidence of the pubertal process. Various
hormonal changes precede these physical changes by years and involve
the hypothalamic-pituitary-gonadal axis that has a feedback loop with
both inhibitory (negative) and stimulant (positive) processes. Several
hormones are secreted by the hypothalamus, as noted in table 2. Many of
these hormones are short acting and are released during late childhood at
night, with increasing pulsatile frequency into the portal circulation of
the hypothalamus.
GnRH pulsatile secretion from the arcuate nuclei in the
hypothalamus eventually leads the anterior pituitary to release the
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gonadotropins, follicular-stimulating hormone (FSH) and luteinizing
hormone (LH). leading to stimulation of the sex (gonadal) steroids,
estrogen, and progesterone. FSH stimulates estrogen production and LH
stimulates androgen production, with resultant development of breasts,
pubic hair, and testicular enlargement in males. A negative or inhibitory
influence on the hypothalamus i induced by estrogen and progesterone.
The menstrual cycle is generally divided into three phases (see figure l):
follicular phase (the first phase), ovulation (the second phase), and the
luteal phase (third or final phase). The fertile window is noted between the
first and third phases. The hypothalamus serves as a generator of puberty,
while GnRH seves as a regulator controlling menstrual cycling.
Table 2. Hormones secreted by the hypothalamus
Gonadotropin releasing hormone (GnRH)
Thyrotropin releasing hormone (TRH),
Growth hormone releasing hormone (GHRH),
Corticotropin releasing hormone (CRH)
Somatostatin
Dopamine

FOLLICULAR PHASE
This initial phase of the menstrual cycle involves ovarian follicle
development and endometrial growth stimulation over an approximate 14
day time period. The main hormone in this phase is estrogen and its
production depends on various hormones, including GnRH, FSH, LH., and
inhibin. GnRH moves through the portal plexus of the hypothalamus to the
anterior pituitary gland to stimulate the production of FSH and LH. The
production rate of these pituitary gonadotropins depends on the
secretion of estrogen and progesterone from the ovaries, as well as
GnRH from the hypothalamus. Hypothalamic, pituitary, or ovarian
dysfunction can all lead to menstrual disorders (7,8).
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Ovarian cycle

Figure 1. The normal menstrual cycle.

OVULATION
Ovarian follicles remain in cycles of growth and atrophy during the
menstrual life of the female. The rise of FSH a few days prior to
menstruation stimulates FSH receptors in ovarian follicles with resultant
development of various follicles (typically 3 to 11), and the follicle with
the highest FSH sensitivity is destined to be the dominant follicle of that
specific cycle (9,10). Estrogen is released from the developing follicle,
while the glycoprotein, FSH, affects the follicular granulosa cells for
ongoing growth as well as increase in LH receptors. The glycoprotein,
LH, affects the theca cells of the maturing ovarian follicles with resultant
androgen production. Androgen to estrogen conversion is enhanced by
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FSH because of increased follicular aromatase activity and further follicle
maturation.
There is a negative feedback loop in which estrogen from the
dominant ovarian follicle reduces pituitary FSH production while a
positive feedback loop allows increased LH secretion. Inbibins A and B are
hormones that are secreted by the ovarian follicle with resultant pituitary
feedback to reduce FSH production, while activins raise follicular
sensitivity to LH (11). The result is continued maturation of the dominant
follicle over that of the other maturing follicles. Levels of estrogen rise until
approximately the first 14 days (day 13 or 14) of tile menstrual cycle, when
a critical estrogen level is reached that induces a major increase in LH (LH
peak ot surge) and resultant ovulation.
The ovulatory part of the menstrual cycle usually occurs over a 1 to
2 day time period and initiates the final menstrual phase, the luteal phase.
The LH surge that occurs in the middle of the normal menstrual cycle
leads to ovulation and the release of the oocyte from the dominant ovarian
follicle and also the resumption of meiosis of the oocyte. Gradual
progesterone increase is noted during the 24 hours prior to and after
ovulation and if pregnancy does not occur, the follicle becomes the
corpus luteum that mainly produces progesterone in a sustained fashion.

LUTEAL PHASE
The surge of LH production occurs in the middle of the menstrual cycle,
resulting in ovulation that lasts 1-2 days and creates a window of fertility of
approximately 6 days; the length of the fertile window depends on various
factors, including gynecological age and actual menstrual length. The
dominant ovarian follicle is released and becomes the corpus luteum,
producing persistent secretion of progesterone over a timeline of
approximately 12 days, unless normal pregnancy occurs with resultant
human chorionic gonadotropin (hCG, HCG) production. Ovulationinduced progesterone secretion leads to a period of altered glandular
secretion and stromal changes, preparing the endometrium for possible
implantation of a blastocyte. The increased progeste-rone reduces
pituitary FSH and LH secretion via a negative feedback loop and also
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reduces GnRH pulsatile secretion that results in less gonadotropin
secretion (i.e., FSH and LH) (12).
The rise in estrogen in the early follicular phase leads to estrogen
binding with endometrial receptors, growth factor stimulation with
resultant blood vessel stabilization and growth of endometrial tissue,
including spirol arterioles, stroma, and glands. Post-ovulatory rise in
progesterone leads to transformation of the endometrium from a
proliferative to a secretory state, with glands that are more and more
tortuous, with production of secretions rich with glycogen and preparing
for implantation. The endometrium becomes edematous and very
vascular.
If pregnancy does not occur, the natural life of the corpus luteum
ends on the fourteenth day of the luteal phase and as it involutes, there is
a dramatic reduction in progesterone that induces menstruation. As the
progesterone production is reduced, pulsatile GnRH production
rejuvenates and a new menstrual cycle is reborn with the potential of
another pregnancy. Menstruation (menstrual period; menses) is the term
which refers to the bleeding event which results when the endometrium
desquamates, due to the withdrawal of estrogen and progesterone.
Initial effect of hormone withdrawal is reduction of half of the
endometrial mass tissue because of fluid absorption and vasoconstriction
of spiral arterioles, mainly under the influence of prostaglandin F2α
(PGF2α) and endothelin-1 with resultant reduction in blood now. The
periodic vasoconstriction (over 24 hours) and relaxation of endometrial
arterioles results in endometrial ischemia that helps to induce
local release of cytokines (as tumor necrosis factor alfa) and other signaling
molecules (13). There is also loss of hyaluronic acid and water from the
regressing endometrium, as well as major extracellular matrix destruction
noted just before and during menses (14). Also noted is activation of
proinflammatory cytokines and matrix metalloproteinases (MMPs:
MMP-I, MMP-3, MMP-9) in the endometrium that contribute to tissue
breakdown independent of the vasoconstriction physiology (11,15, 16).
Finn (17) has contended that the process of menstruation is an
inflammatory one with edema of tissues, migration of leukocytes, and
decidual cells suggesting granulation tissue fibroblasts. Indeed, there are
various inflammatory cells present, including macrophages, granulated
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lymphocytes, and polymorphonuclear leukocytes that contribute to
vascular permeability and breakdown of endometrial tissue via release of
various regulatory molecules. Interleukin-8 is a cytokine that leads to the
release of various chemicals, such as tryptase and chymase, with
resultant influence on leukocyte migration to the endometrium that help
induce endometrial breakdown.
Essential to normal menstruation is normal blood coagulation with
generation of thrombin-induced fibrin that is stimulated by tissue factor
in the endometrium via the extrinsic pathway. Tissue factor rises in
decidual cells of the endometrium because of progesterone and tissue
factor foils with the fall of progesterone. It is noted that fibrin-platelet plugs
are found in superficial blood vessels and not in the surrounding
tissue because of endometrial fibrioolytic pathways. A balance is
necessary to be achieved between the coagulation factors' production
that controls bleeding and the process of fibrinolysis that stops clot
organization and intrauterine adhesion. Indeed, the coagulation process is
mainly one of hemostasis in the secretory menstrual phase and a
fib1inolytic process in overt menses. As apoptosis and necrosis continues,
endometrial tissue shrinks and much of this layer breaks down into
fragments with much blood and fluid that are expelled into the uterine
cavity and lost.
Eventually the blood Joss stops, and repair of tissue occurs because
of increasing estrogen with local growth factors release and sustained
vasoconstriction. VEGF (vascular endothelial growth factor) is an
angiogenic chemical that is induced by hypoxia and is vital to the overall
endometrial repair process (18). The process of endometrial angiogenesis
is a complex one and related to influence of VEGF and the fibroblast
growth factors that are produced, in part, by the migration of leukocytes to
the endometrium (19-21).
After ovulation, the corpus luteum leads to progesterone production
that changes the endometrium to a secretory state, with a decidualized
stroma that has increased edema and vascularity along with glands that are
tortuous and abundant in glycogen. As the corpus luteum dies, both
estrogen and progesterone rapidly decrease, with resultant endometrial
atrophy and loss of approximately 50% endometrial mass in 24 hours.
Vascular vasoconstriction leads to the end of menstruation. Disruption in
this process of angiogenesis leads to menstrual dysfunction and abnormal
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bleeding. Failure to develop a fully mature secretory endometrium
characterizes a luteal phase defect (22,23).

DYSFUNCTIONAL UTERINE BLEEDING
Dysfunctional uterine bleeding (DUB), one of the most urgent adolescent
gynecological conditions, refers to prolonged, excessive, or unpatterned
uterine endometrial bleeding not caused by uterine anatomical conditions
(1,24). Causes of abnormal menstrual bleeding are noted in table 3 and
include coagulation disorders, infections, trauma, pregnancy
complications, systemic conditions, local lesions, and various
reproductive tract pathology; these etiologies need to be eliminated
before using the diagnosis of DUB (1,6,25). Premature menarche has
been noted on occasion in girls in which one or more episodes of vaginal
bleeding occurs without evidence of pubertal changes; it is usually
idiopathic but may be associated with hypothyroidism or other causes
(26,27).
Approximately 15% of adult women present with DUB and this
number is much higher in the adolescent female population. One
questionnaire-based study of 1,410 high school females with a mean age
of 16.7 years revealed that 37% had a history of heavy menstruation,
38% had a family history positive for heavy menses, and 22% of these
adolescent females had been treated with hormonal therapy for their
menstrual condition (28). Complications in cases of coagulation
disorders include anemia, spontaneous bleeding into joints or muscles,
increased bleeding after surgery, and increased absence from school
and/or work.
A major cause of DUB in adolescents is anovulatory irregular
menstruation, typically due to lack of the positive feedback effect of
estradiol and absence of ovulation at menarche and for 1-5 years after
menarche (29). For example, research notes that anovulation occurs in
55% to 82% of menstrual cycles in adolescents at menarche and for 2
years after menarche while anovulation occurs in 30% to 45% of menses
from years 2 to 4 after menarche, and no more than 20% of menses from
years 4 to 5 (30).
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Levels of the glycoproteins LH and FSH, as well as the hormones
estrogen and progesterone are below that of normal adult female levels
during the first year after menarche. While estradiol levels increase to
normal adult levels by year two post-menarche, progesterone levels
remain low for up to 5 years after menarche, and LH/FSH are at adult
levels by year 5. LH secretion is mainly nocturnal and episodic before
puberty and as puberty develops. LH secretion increases and normal
timing of LH pulses are necessary for developing normal ovulatory
cycles.
Increased estrogen leads to less GnRH with reductions in FSH and LH
and resultant less stimulation of estrogen that can lead to
vasoconstriction and atrophy of thickened endometrium and resultant
heavy, prolonged menstrual bleeding. Estrogen that is unopposed by
progesterone leads to growth of the endometrium that eventually cannot
be supported by its blood supply and results in partial endometrial
breakdown with irregular shedding and bleeding. Failure of ovulation
and resultant unopposed estrogen leads to decreased vascular tone of
endometrial blood vessels, with inhibition of vasopressin release and
resultant vasodilatation and increased menstrual bleeding (31).
Unopposed estrogen also induces VEGF production with resultant
angiogenesis (31). The endometrium that is not exposed to progesterone
produces less prostanglandin (PG) and a greater ratio of PGE than PGF.
Excessive blood loss may also be due co increased development of
endometrial nitric oxide (endochelium-derived relaxing factor) that is
stimulated by unopposed estrogen (32).

Table 3. Causes of abnormal menstrual bleeding in adolescents*
(Exclude rectal, urethral. and other perineal bleeding)
Vaginal or uterine abnormalities
Trauma (coitus, rape, abuse)
Foreign body (IUD, tampon, etc)
Infection
Vaginitis (trichomonas, gonorrhea)
Cervicitis
Endometrilis (tuberculosis)
Pelvic inflammatory disease
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Sexually transmitted condylomata (HPV) ofcervix or vagina
Tumor
Botryoid sarcoma
Polyps (uterine, cervical)
Ovarian cyst or tumor (mature teratoma, endometrioma)
Leiomyomatosis
Clear cell carcinoma of cervix or vagina (DBS)
Other ovarian malignancy and metastatic malignancy
Endometriosis
Congenital malformations of utems
Complications of pregnancy
Threatened or spontaneous abortion
Ectopic pregnancy
Molar pregnancy
Induced abortion
Coagulopathy
Generalized
Thrombocytopenia (idiopathic thrombocytopenic purpura; leukemia;
lymphoma; aplastic anemia, hypersplenism)
Platelet dysfunction (Glanzmann's disease)
Clotting disorders (hemophilia; von Willebrand's disease; other
coagulation factor deficiencies)
Uterine production of menstrual anticoagulant,
Dysfunctional uterine bleeding
Normal variation
Midcycle ovulatory bleeding
Early postmenarcheal anovulation
Early postmenarcheal estrogen irregularities
Chronic anovulation
Exogenous steroids
Oral contraception
Midcycle breakthrough bleeding
Relative luteal progesterone deficiency
Progestogens (oral agents; Norplant; Depo-Provera)
Continuous estrogens
Other drugs
Danazol
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Spironolactone
Anticoagulants
Platelet inhibitors
Chemotherapy drugs
Natural hor.01ones fromplant extracts (DHEA, Dong Quai,
Yam Extract)
Systemic diseases
Hyperthyroidism or hypothyroidism
Adrenal insufficiency
Cushing's syndrome
Diabetes mellitus
Chronic liver disease
Crohn's disease; ulcerative colitis
Chronic renal disease
Systemic lupus erythema1osus
Ovarian failure
Hyperprolactinemia
Androgen excess
Exogenous androgens, PCOS, congenital adrenal
hyperplasias
Androgen producing ovarian oradrenal tumor
Estrogen excess
Granulosa-theca cell tumor of the ovary
Other tumors
Hypothalamic
Emotional stress
Physical stress, especially exercise
Ovulatory
Short luteal phase
Prolonged luteal phase (Halban's disease)
Luteal progesterone insufficiency
Abbreviations: lUD = Intrau1erine device; HPV = human papillomavirus;
DES: diethylstilbestrol
•
* Reprinted, with permission from: Greydanus DE. Breast and gynecological
disorders. In:HofmannAD, Greydanus DB, eds. Adolescent medicine, 3rd
ed. Stamford, CT: Appleton Lange, 1997:547.
Though anovulation is the main stimulant to DUB, abnormal
menstrual bleeding can also occur in ovulatory states, as, for example, in
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the Halban syndrome or prolonged progesterone in which a persistent
corpus luteum cyst leads to 6 to 8 weeks of amenorrhea, followed by
irregular menses (22,23).

COAGULATION AND DUB
An important aspect of normal blood clotting in controlling menstrual
bleeding is the generation of thrombin-induced fibrin, as induced in the
endometrium by tissue factors utilizing the extrinsic pathway of
coagulation (6). Fibrin-platelet plugs develop in superficial blood vessels
due to endometrial fibrinolytic pathways and there is a balance between
coagulation factors that control bleeding and fibrinolysis to prevent
organization of clots and intrauterine adhesion. In menstruation, there is
a shift to fibrinolytic mechanisms with endometrial breakdown and
shedding of uterine material that is expelled with variable loss of tissue
and blood.
Eventually, prolonged vasoconstriction occurs along with local
growth factors that are released and increase in estrodiol production that
stops blood loss. Repair of epitheliurn develops with the production of
angiogenic factors as VEGF (vascular endothelial growth factor), that is
stimulated by hypoxia (6). Angiogenesis in the endometrium involves the
formation of new vasculature from pre-existing vessels because of the
effects of VEGF and FGF (fibroblast growth factor). Migratory
leukocytes are an important part of this cyclical angiogenesis, as noted
earlier.

CONGENITAL COAGULATION DISORDERS
Severe dysfunctional uterine bleeding may be the first indication of an
underlying bleeding disorder (see table 4). Studies note that 19% to 28%
of adolescents who are hospitalized due to acute menstrual bleeding have
a coagulation disorder (33,34 ). Approximately 80%-85% of inherited
bleeding disorders are Hemophilia A (F (factor] VIII deficiency), Von
Willebrand's Disease (vWD) and Hemophilia B (F IX deficiency)
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(1,9,35,36). Approximately 15% are congenital bleeding disorders that
include deficiencies of fibrinogen, prothrombin, and factors V, VII, X,
XI, XIll and combined V + VII (1,36-38). Approximately 20-30% of those
with menorrhagia have platelet dysfunction while 13%-17% have
von Willebrand's disease (25).

Von Willebrand's Disease (vWD)
VWD is an autosomally inherited condition affecting 1% to 3% of the
population and caused by a gene on chromosome 12. VWD is either a
quantitative or qualitative defect of the production of vW factor; this
factor is a protein needed for normal platelet adhesion at injured
endothelium and for preservation of circulatory Factor VIII (36). Clinical
findings and laboratory evaluation will identify vVD including
Quantitative types 1 or 3 and Qualitative 2, with its various subtypes: 2a,
2b, 2m, and 2n.
Table 4. Coagulation disorders

Hemophilia A (F (factor] VTIIdeficiency)
Hemophilia B (FIX deficiency)
Von Willebrand's Disease (vWD)
Platelet function defect
Thrombocytopenia
Factor deficieocie : F V, XI, XIII, VII, II
Fibrinogen deficiency
Others
The mildest vWD type is 1 with only moderate vW factor reduction
and this involves 70% to 80% of this disorder. Both types 1 and 2 are
often not identified until adolescence or adulthood, in which suspicion
arises after bleeding is noted with severe trauma or surgery. Suspicion
may also develop because the adolescent female presents with
menorrhagia as her first clinical evidence of vWD. The first report of
vWD was by Erik von Willebrand in 1926 in which 16 of 23 affected
family members were female and the index case was a young adolescent
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female, who died at age 13 years from uncontrolled bleeding during her
4th menstrual period; she probably was a type 3 vWD (39). A number of
adult females with vWD eventually resort co hysterectomy to stop the
severe menorrhagia.

Hemophilia
Hemophilia occurs in I in 5,000 males and is caused by genes at the long
arm tip of the X chromosome; Hemophilia A is deficiency of Factor VIII
while Hemophila B is deficiency of Factor IX (36). Normal plasma
levels of F VIII and F IX are 50% to 150%. Hemophilia can be divided
into three levels of severity: mild, moderate, and severe. Mild hemophilia
is defined by a factor level over 5% and represents 20% in contrast to
moderate hemophilia with levels of 1% to 5% (15% of cases) and severe
with factor levels under 1% (65% of cases). Mild hemophilia may not be
diagnosed until adolescence.

DUB AND COAGULATION DISORDERS
Table 5 lists laboratory tests useful for screening adolescent females with
severe menorrhagia in which a coagulation disorder must be considered
as part of the differential diagnosis (1,9,36,40). Coagulation disorder
prevalence in those with severe menorrhagia varies in published studies,
depending on the population studied. In one study of 1,410 high school
females, though 37% noted heavy menses, only 8 had an actual bleeding
disorder diagnosis (28). The classic paper by Claessens and Cowel in
1981 (41) noted that 19% of those who were hospitalized because of
severe menorrhagia had a coagulation disorder, while 28% had a
coagulation disorder if there was severe anemia, and 45% if severe
bleeding with hospitalization occurred with the first menstrual period
(menarche) (versus 65% in Kadir's 1998 study) (42). In Falcone's 1994
study 3% of adolescent females with DUB were diagnosed with a
coagulation disorder, 41% received blood transfusions, 93% improved
with hormonal treatment, 8% were managed with a D and C. Also, 34%
received a D and C (dilation and curettage) (43).

332

Donald E. Greydanus, Hatim A. Omar, Artemjs K. Tsitsika et al.

The mildest vWD type is 1 with only moderate vW factor reduction
and this involves 70% to 80% of this disorder. Both types 1 and 2 are
often not identified until adolescence or adulthood, in which suspicion
arises after bleeding is noted with severe trauma or surgery. Suspicion
may also develop because the adolescent female presents with
menorrhagia as her first clinical evidence of v\VD. The first report of
vWD was by Erik von Willebrand in 1926 in which 16 of 23 affected
family members were female and the index case was a young adolescent
female, who died at age J 3 years from uncontrolled bleeding during her
4th menstrual period; she probably was a type 3 vWD (39). A number of
adult females with vWD eventually resort to hysterectomy to stop the
severe menorrhagia.
Table 5. Laboratory screening for severe menorrhagia

Initial Screening
Complete blood count with differential; hCG testing
Platelet function analysis (PFA) (Has replaced the old bleeding time
test)
Fibrinogen
Bleeding Studies
a. Prothrombin time (PT)
b. Activated partial thromboplastin time (aPTT)
Secondary Screening*
vonWillebrand's factor antigen
Factor VITIactivity
Factor XI antigen
Ristocetin C co-factor
• Platelet aggregation studies
* (severe or prolonged bleeding, menorrbagia with menarche, abnormal first
tests)

Severe menstrual bleeding was reported in one study of 102 females
with vWD (versus 88 controls) in 74% of those with vWD versus 6% of
the controls (44). TI1ose with vWD have a higher incidence of
menon-hagia, severe bleeding postpartum, migraine headaches, and
arthritis. Such a negative impact of vWD is noted in other studies. For
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example, one report studied type I vWD patients using a patient survey
of 99 patients (81 still menstruating) with mild disease versus 15O
controls. In this study, those with vWD had a statistically increased
history of anemia, number of tampons or towels used in menses, number
with stained clothes due to menses, and birth-related bleeding that
required blood transfusions (39). In the group with vWD, there was a
reduced quality of life due to increased bleeding problems, only 50%
reported hormonal management that was effective, 17% reported that a D
and C was needed, and 13% had hysterectomy (39).
In another study of 116 female with inherited bleeding disorders
(IBD) versus 69 controls. 66 had vWD (74% with menorrhagia), 30 were
carriers of hemophilia (57% with menorrhagia) and 20 had Factor XI
deficiency (59% with menorrhagia); 29% of the controls who did not
have IBD had menorrhagia (45,46). There was no association between
the blood loss degree (as measured by the Pictoral Blood Assessment
Chart) and disease severity in hemophilia or Factor XI deficiency. The
degree of blood Joss could not be predicted based on the vW factor
activity (vWF:Ac) (45,46).
The duration of the menstrual period increases significantly in
females with IBD, in contrast to those without IBD; there is an increase
in menstrual flooding in those with IBD, but no difference in clot passage
is reported. In those with IBD, 47% had seen their clinician because of
the excessive menstrual bleeding, 36% received hormonal therapy due to
menorrhagia and 27% received surgery (such as D and C or
hysterectomy) (45). Also reported was that the use of the PBAC (Pictoral
Blood Assessment Chart) is not reliable for assessing blood loss (45).
One study looked at the the quality of life (QOL) in 99 with IBD in
contrast to 69 controls that utilized a questionnaire asking about daily
activities, general health, dysmenorrhea, and QOL during menstruation
(42). In this study, there were 57 with vWD, 17 were Hemophilia
A carriers. seven were Hemophilia B carriers, and 18 had Factor XI
deficiency. The QOL was statistically lower if menorrhagia was present
in those with IBD, if menses lasted eight or more days, and if there was
menstrual flooding or passage ofclots (see table 6) (42).
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Table 6. Quality oflife for 99 patients with inherited bleeding
disorders (42)

39%
47%
38%
40%
51 %

had cut down on time at work and other activity due to menses
felt they accomplished less during menses than they would like
felt they were limited in work
needed extra effo1t in work
had moderate, severe or very severe dysmenorrhea

DUB PROGNOSIS
DUB in adolescent females usually results from anovulatory
mcostmation because of immaturity of the HPO axis (1,47-50). Most
adolescents develop regular ovulatory menses between one and five
years after menarche leading to regular menstrual patterns. The classic
Southam and Richart 1966 study (51) found that if normal menstruation
does not develop within four years of menarche, normal menstrual
function will probably not develop in adult life. Many of these adult
females had reduced reproductive potential and high rates of endometrial
cancer, as there seems to be an underlying disease process causing the
chronic bleeding abnormality.

DUB MANAGEMENT
Figure 2 outlines an evaluation process for adolescents with DUB. The
management is dependent on the underlying cause and also the degree of
anemia that may or may not be present; hormonal management is
provided if necessary to control the abnormal bleeding (7). Mild anemia
is defined as a hematocrit between >33% and < 36% or a hemoglobin >
11 g/dl but < 12g/dl. Moderate anemia is defined by a hematocrit
between 27% and 33% or hemoglobin between 9 and 11 g/dl. Severe
anemia refers to a condition with a hematocrit under 27% or a
hemoglobin under 9 g/dl or rapidly dropping. Management of DUB in
adolescent females due to anovulatory menstruation is now discussed.
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Absence of anemia or mild anemia
Reassurance and watchful waiting is usually recommended in situations
of anovulatory DUB if the patient is not overly concerned and there is no
or only mild anemia. A menstrual calendar can be kept by the youth to
better follow her menstrual panerns. Iron supplementation can be
prescribed for mild anemia, such as ferrous sulfate at 300 mg three times a
day; side effects adding iron are noted in table 7 (1,6). Constipation
from iron supplementation may be prevented by adding a stool softener
and a low release form of iron may lower the overall side effects. A 30% to
50% reduction may be seen if non-steroidal anti-inflammatory drugs
(NSAIDs) are given at menses because of a direct endometrial effect on the
(potent
and
thromboxane A2
vasoconstrictor)
balance
of
prostaglandin I2 (vasodilator). Thromboxane is a member of family of
lipids called Eicosanoids that are produced in platelets (see table 8).

Table 7. Adverse effects of iron supplementation
Black stools
Constipation (add stool softener to prevent)
Diarrhea
Nausea and emesis
Worsenjng ulcers/colitis

Table 8. Thromboxane production
l) Arachidonjc Acid → Endoperoxides
2) Endoperoxides → Toromboxane A2 → Thromboxane Bz(Platelets)
3) Endoperoxides → Prostacyclin (PGI2)
4) Vasoconstrictor
5) Facilitates platelet. clumping

336

Donald E . Greydanus, Hatim A. Omar, Artemis K. Tsitsika et al.
History and Exam

Gynecologic age
≤ 2 years

Menstrual calendar
Multivitamin with
iron
Reevaluate in 1-2
months

Gynecologic
age ≥ 2 years

CBC with differential, retic, platelets
Consider: urine or serum pregnancy
test, STD screens

Labs: Free T4, TSH
prolactin, free testosterone *†

↓CBC, ↓platelets,
↑retic

Cycle with OC's
(see DUB
treatment-Table 6)

Normal labs
abnormal CBC
and platelets

Abnormal labs
normal CBC
and platelets

Normal labs
normal CBC
and platelets

Abnormal TSH,
prolactin

Abnormal free
testosterone

Menstrual calendar
Multivitamin with
iron
Reevaluate in 1-3
Months

Refer for
endocrine

Cycle with
OC's

Cycle still
abnormal

LH, FSH*

If
abnormal,
refer

If normal, cycle
with OCs or
patch

Used and adapted with permission from: Joffe A, Blythe MJ. Handbook of
adolescent medicine. Adolesc Med 2003; 14(2):294, figure 1; Greenfield TP,
Blythe MJ. Menstrual disorders in adolescents" In: Greydanus DE, Patel
DR, Prall HD, eds, Essential adolescent medicine. New York, McGraw-Hill,
2006:602.
Figure 2. Evaluation of dysfunctional uterine bleeding in adolescent patients
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Oral or 1ransdermal con1racep1ion (pills or patch) can also be an
option m improve the DUB (especially if the adolescent is sexually
active and it prevents unwanted pregnancy at the same time) (52-54).
Instead of using oral contraceptives, some clinicians prescribe oral
equine estrogen (2.5 mg for 21-25 days); 10 mg medroxyprogesterone
acetate is then added over the last seven days of the cycle. An alternative
is to use oral progesterone for the last 10 days of the menstrual cycle in
order to preve1Jt the effects of unopposed estrogen and allow endometrial
stabilization; a regular sloughing of the endometrium then occurs as
progesterone is withdrawn (55). Adverse effects of cyclic oral progestin
therapy include bloating, increased acne, hyperphagia with weight gain,
and ineffective contraception. Alternatives used by some include a
natural progestin or progesterone developed from wild yams or a finely
ground or miconized form (Prometrium) used to avoid or reduce side
effects, though there is no underlying research for their use (1).
Dcpo-medroxy-progesterone acetate (DMPA; Depo-Provera) is not
typically recommended for youth with DUB. because it may cause
irregular bleeding that may later evolve into amenorrhea. As it is given in
an intramuscular form, it should not be a first option in those with a
coagulation disorder. However, DMPA may be provided in unique
situations, such as a sexually active female with DUB and systemic lupus
erythematosus who is on coumadin (56). Side effects of DMPA include
weight gain, decreased bone mineral density, worsening of depression,
protracted ovarian suppression, and hair loss.

Moderate anemia
DUB that induces moderate anemia may be controlled with an oral
contraceptive pill with 30-35 mcg ethinyl estradiol (6,52,57). As noted
previously, estrogen controls menstrual bleeding by binding to
endometrial receptors, stimulating specific growth factors, and producing
vasculature stabilization; estrogen stimulates the development of the
glands, stroma, and spiral arterioles in the endometrium. The oral
contraceptive (OCP) can be given in a dose of 2-4 pills a day, until the
bleeding is stopped and then gradually tapered over 2 to 3 weeks (see
table 9). The OCP can be stopped to allow withdrawal bleeding and then
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added again as a once-a-day pattern for 3 to 6 months, in order to allow
menstrual regulation and improvement of the anemia with iron
supplementation. Increased estrogen may lead to nausea and emesis, thus
necessitating the addition of an anti-emetic agent.
Table 9. Schedule of oral contraceptives to control moderate to
severe DUB
1. Four times a day (with an anti-emetic) until the bleeding stops
2. Three times a day for 4 days
3. Twice a day for two to three weeks
4. Allow a controlled withdrawal bleed
5. Start the oral contraceptive and oral iron supplements at once a day
for 3 to 6 months
Table 10 lists various oral progesterone-only patterns that are
preferred by some clinicians; high doses may be necessary to induce
cndomctrial atrophy and estrogen is added for several days to prevent
unwanted endometrial break-through bleeding when progesterone-only
medicat.ioos are used. As noted before, iron supplementation can be
given for 3-6 months to correct depleted iron stores and a stool softener
added to prevent constipation.
Table 10. DUB control with progesterone-only agents
A. Medroxy-progesterone acetate (MPA)

1. 10 mg q 4 hours, then QID-4 days, TID-3 days, BID-14 day)
2. high dose may be necessary: 40-80 mg per day or 100 mg Depo
IM/day
B. Norethindrone acetate (Aygestin)
1. 10 mg q 4 hours, then q6-8 hrs to 12 hours; taper as bleeding
decreases
2. May stay on5 mgq 12h rs for months if necessary with ↑ if
necessary (as teen with aplastic anemia & low platelet count)
3. 0.35 mg OD-BID for breakthrough bleeding
C. Megestrol acetate (80 mg BID may be needed)
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Severe anemia
If severe anemia has developed as a result of DUB, emergency
management may be necessary that includes provision of intravenous
fluids and and blood products. Intravenous Premarin (conjugated equine
estrogens) is given by some at a dose of 25 mg every 4 hours; Two doses
are usually effective in 75% of patients and only 2-4 doses are usually
needed, because of the hemostasis that results because of direct clotting
effects with increased production of fibrinogen, Factor V and Factor IX
activity and increased aggregation of platelets. Many clinicians will not
use intravenous estrogen because it is not usually needed and because of
the increased risk for thromboembolism that may be present when high
doses of estrogen are used. An antiemetic agent must be added to offset
the estrogen-induced nausea and emesis. A progesterone is added to
allow a regulated menstrual bleeding.
Instead of intravenous estrogen, many clinicians use oral
contraceptives as outlined in table 9. Fortunately, such hormonal
management is effective in controlling DUB in over 90% of such
situations. If these measures are ineffective, other causes must be
considered, such as coagulation disorders (9,43). Other medications can
be added, such as Desmopressin acetate or antifibrinolylics, as
considered in the next section.

MANAGEMENT OF DUB DUE TO COAGULATION
DISORDERS

Factor replacement therapy
Table 11 lists methods of DUB management in patients with coagulation
disorders (1,6,58,59). Control of menstrual bleeding is based on working
with the delicate balance between thrombosis and bleeding. Hemostasis
physiology involves three basic phases: vascular phase (blood vessel
vasoconstriction), platelet phase (the primary hemostatic mechanism
involving platelet plug formation), and the fibrin thrombus formation
phase (60). The basis of management is factor replacement therapy
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involving either factor VIII, Factor IX, or vW factor in which factor
levels should be at 30% or more for minor bleeding and 100% for major
bleeding as noted with surgery or intracranial hemorrhage. Recombinant
Factor Concentrates are preferred if available; otherwise, pathogen-safe
plasma-derived concentrates are used. Non-steroidal inflammatory drugs
(NSAIDs) are not effective in reducing blood loss in those with inherited
bleeding disorders.
Table 11. Control of DUB in inherited coagulation disorders
I. Factor replacement therapy
2. Intranasal DDA VP
3. Antifibrinolytics
4. Oral contraceptives
5. Levonorgestrel-releasing IUD (Mirena)

Intranasal DDA VP
The treatment of choice is intranasal DDA VP (Desmopressin acetate; 1deamino-8-D-arginine vasopressin) since it raises plasma concentrations
of Factor VIII and vWF 2 to 6 fold by way of endogenous release of
these factors. Intranasal DDA VP is best for those with Type 1 vWD with
normal vWF available from storage sites; however. it can also help with
menorrhagia in those with mild hemophilia and other von Willebrand
types (36,38).
Three forms of DDA VP are available: intranasal, subcutaneous (SC),
and intravenous (IV). Concentrated intranasal DDAVP (Stimate) is made
as a 1.5 mg/ml preparation with two-thirds the effect of the IV form and
the formulation used to treat diabetes insipidus should not be used for
patients with coagulation disorders and menorrhagia. A dose of 300 µg
(2 metered doses) is used for those over 50 kg and the patient is then
observed for 60 to 90 minutes after giving the medication. Side effects of
intranasal DDAVP are listed in table 12 and include mild fluid restriction
necessitating monitoring of the urinary output and daily weights for
urinary retention. If the intravenous form of DDAVP is used, the dose is
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0.3 g/kg given in 25-50 ml normal saline over 15-20 minutes; peak
action occurs in 30 to 60 minutes.
Table 12. Side effects of intranasal DDAVP
1. Facial flushing (asymptomatic)
2. Thrombosis (rare)
3. Hyponatremia (more common in children, if given repeatedly, or too
much fluid)
4. Headaches
5. Nausea
6. Weakness

Antifibrinolytics
Antifibrinolytics (i.e., epsilon-aminocaproic acid (Amicar) or tranexamic
acid) are also used as adjunctive management for menorrhagia in
hemophilia, as well for mucosal bleeding (epistaxis, dental extraction,
oral bleeding) (25,36,38). Antifibrinolytics improve coagulation by
preventing clot degradation in areas high in fibrinolytic activity,
inl1ibiting fibrinolysis, and by preventing change of plasminogen to
plasmin. They can be taken along with DDAVP, factor replacement
therapy, and coagulation Factor IX concentrates. Antifibrinolytics should
not be taken immediately with prothrombin-complex concentrates
(PCCs), because of increased risk for clot formation; however, they can
be taken 4-6 hours after PCCs are stopped. Side effects of
antifibrinolytics are noted in table 13.
Table 13. Side effects of antifibrinolytics
l. Nausea and emesis
2. Headaches
3. Abdominal pain
4. Avoid with urinary tract bleeding due to potential for intrarenal clots
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Tranexamic acid (Cyklokapron) improves menorrhagia by
significant lowering of plasminogen activator activity and plasmin activity
in menstrual fluid. It is used in Europe and given orally at a dose
of 20-25 mg/kg q 6-8 hours orally (maximum: 1.5 grams) or at an
intravenous dose of 10 mg/kg q 8 hours (Max: 1 gram); the IV form is used
in the United States. Epsilon-aminocaproic acid (EACA; Amicar) is
prescribed as oral medication (flavored syrup or tablets) at a dose of 50100 mg/kg q 6 hrs (maximum is 24 grams per day). Gastrointestinal side
effects can be increased at higher doses.

Oral contraceptives
Females with DUB and inherited bleeding conditions can also be treated
with oral contraceptives (OCPs), since they raise Factor VIII activity
(FVIII:Ac) in hemophilia carriers and, in vWD patients, OCPs ameliorate
hemostatic deficiencies, raise Factor VIII/vWF-ristocetin cofactor
activity, and ameliorate prolonged bleeding time (39,45,52,61). The
benefits and risks of using estrogen must be considered when prescribing
oral contraceptives; for example, some will use estrogen for females with
a history of deep vein thrombosis if taking coumadin (56,62).

Levonorgestrel-releasing IUD
The levonorgestrel-releasing IUD (Mirena IUD or Mirena coil)
releases a small dose of levonorgestrel that has a number of effects and
benefits, as listed in table 14 (38,56,63,64). One of the benefits is
improvement of DUB in females with coagulation disorders, though its
historic link to pelvic inflammatory disease has limited its use in
adolescent females (52,56,62).

Other management options
Various other options have been used in adult females to control irregular
menstrual bleeding, including danocrine (Danazol), GnRH agonists
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(buserelin, leuprolide [Depo Lupron], naforelin [Synarel]), D & C
(dilation and curettage) and hysterectomy (38,65). Danocrine is a
synthetic hormone prescribed to manage endometriosis, breast cysts, and
heavy menstrual bleeding in adult females. Danocrine suppresses
estrogen and prevents menstruation, though ir is teratogenic and can lead
to masculinization. It has limited research support in adolescents. Also
with limited research data in adolescent is the use of GnRH agonists
used in adult females to stop ovulation.

Table 14. Effects and benefits of levonorgestrel IUD
A.
•
•
•
•
•
•
B.
•
•
•
•
•
•
•
•
•
•

Contraceptive effects
Prevents fertilization
Interferes with ovum development
Interferes with sperm movement and ability to penetrate ovum
Inhibits sperm survival
Helps prevent egg release
Thickens cervical mucus
Benefit
Effective contraception for 5 years
Eventual reduction in menstrual flow
OK for those with coagulation disorders
Up to a 90% reduction in bleeding
20%-50% with no menses after one year
Good for those with Mental retardacion/Developmenral
disorders
Frequent amenorrhea
Decreased dysmenorrhea
Decreased premenstrual syndrome
Very low rates of infectious complications
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Table 15. Causes of primary amenorrhea

• HYPOTHALAMlC-INDUCED
Stress
Drugs
Exercise
GnRH deficiency
Obesity
Eating disorders
Others
• PITUITARY-INDUCED: HYPOPITUITARISM
Congenital (idiopad1ic)
Head trauma
Tumor (prolactinoma)
Ochers (as hemochromatosis)
• OVARIAN-INDUCED
Gonadal dysgenesis
Polycystic ovary syndrome (PCOS)
Tumor
Resistant ovary syndrome
Others
Ovarian failure
Radiation or chemotherapy-induced
Premature failure
Autoimmune oophoritis
• OTHERS
Adrenal gland tumor
Congenital adrenal hyperplasia (complete or partial)
Androgen insensitivity syndrome (AIS)
True hermaphroditism
Hyperthyroidism or hypothyroidism
Uterine synechiae
Pregnancy
Vaginal agenesis
Transverse or longitudinal vaginal septum that obscruct the outflow
lmperforate hymen
Cervical agenesis
Others
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AMENORRHEA
Amenorrhea or absence of menstrual flow is divided into primary and
secondary amenorrhea (66,67). Primary amenorrhea is defined as lack of
menstruation by age l4 at sexual maturity rating (Tanner stage) 1 (having
no sexual maturation) or by age 16 with some sexual maturation; lack of
menses 3-4 years after thelarche may also be considered to be primary
amenorrhea (1). Primary amenorrhea has a prevalence o f 3 per 100
adolescents in the United States. Secondary amenorrhea points to menses
cessation for at least 4 to 6 months after regular menses bas been
established or for a time equal to a total of three or more previous
menstrual cycles. Oligomenorrhea (see table 1) is defined as menses that
occur at intervals over 45 days and are usually irregular as well. Causes
of amenorrhea and oligomenorrhea are the same in most cases and are
now considered in the next section.
Table 16. Clinical classification of amenorrhea in the adolescent*
I. Primary Amenorrhea with Pubertal (Sex) Delay
A. Gonadal malformation
l. Turner syndrome (Gonadal dysgenesis)
2. Androgen insensitivity syndrome (Testicular feminization
syndrome)
B. Hypothalamic-Pituitary Dysfunction
1.Physiologic Delay (Most common)
2.Functional Disorders: bypothalamic-induced: such as weight
loss, eating disorders, exercise, stress, others
3. Organic Disorders: Prolactinoma, Chronic Illness, others
II. Primary Amenorrhea without Pubertal (Sex) Delay
A. Pseudoamenorrhea
1. lmperforate hymen
2. Transverse vaginal septum
B. Mayer-Rokitansky-Kustcr-Hauscr Syndrome -agenesis of vagina,
cervix, uterus
C. Polycystic Ovary Syndrome (Hyperandrogenemia Syndromes)
D. Chronic Illness (including Thyroid Disorders)
F. Others
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III. Secondary Amenorrhea
Pregnancy (most common)
Hypmbalamic-induced such as weight loss, eating disorders, exercise,
stress, Polycystic Ovary Syndrome (Hyperandrogcnemia Syndromes)
4. Thyroid Disorders
5. Pituitary disorders (Pituitary adenoma)
6. Hypoestrogenemia (ovarian dysfunction orovarian hypofunction)
7. Chronic Illness
8. Others

• Modified and reprinted with permission from: Greydanus DB, Patel DR. The
female athlete: before and beyond puberty. Pediatric Clin North Am
2002;49:553·80.

PRIMARY AMENORRHEA
Etiology
Table 15 lists causes of primary amenorrhea and include physiologic
delay (constitutional growth delay), chronic illness, Turner's syndrome
(gonadal dysgenesis), Mayer-Rokitansky-Küster-Hauser syndrome
(MRKH syndrome), and androgen insensitivity syndrome (1,6,68-71).
The most common cause is physiologic delay. Primary amenorrhea can
be seen in those with hirsutism and virilization, such as seen in polycystic
ovary syndrome (PCOS), mixed gonadal dysgenesis, gonadal
dysgenesis with virilization, congenital adrenal hyperplasia, ovarian or
adrenal tumors, true hermaphroditism and others (see table 15).
Table 16 lists causes of primary amenorrhea based on those with
pubertal delay and those without pubertal delay. Causes of primary
amenorrhea that do not usually cause secondary amenorrhea are included
in table 17. However, there is considerable overlap between disorders
that cause primary versus secondary amenorrhea and a careful evaluation
is necessary for both. Table 18 lists causes of hirsuitism and virilization
in females, while table 19 lists disorders to be distinguished from
hyperandrogenism.
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Table 17. Causes of primary amenorrhea and
not secondary amenorrhea

Androgen insensitivity syndrome
Congenital hydrocephalus
Idiopathic hypopituitarism
Kallmann's syndrome
Laurence-Moon-Bardet-Biedl syndrome
Hermaphroditism
Mayer-Rokitansky-Kuster-Hauser syndrome (Genital tract agenesis)

Medical history
Menarche typically occurs 2-3 years after thelarche with a range of 1 to 5
years, often between Tanner stage 3 and 4: however, approximately 15%
occur in Tanner stage 5. Menarche often occurs within a year of the
mother's menarche. Key questions to explore in an adolescent female
presenting with amenorrhea is whether pregnancy may have occurred
( even if "primary" amenorrhea is being investigated), if there is normal
or low estrogen stale, if there is evidence of excess androgen production,
and if there is an anatomically normal genital tract. The medical history
should review pubertal development carefully and look for evidence of
congenital anomalies, hernia as an infant, systemic illnesses, excessive
exercise patterns, and virilization (i.e., hirsutism, clitoromegaly, scalp
hair thinning, severe acne).
A careful history of the menstrual pattern is important to obtain, in
order to distinguish primary from secondary amenorrhea (1). What is the
sexual history of the patient, looking for previous pregnancies or
abortions? What is the state ofthe patient's nutrition? Is there a history of
endomctrial destruction from a dilatation and curettage (Asherman' s
syndrome) or stenosis of the cervix from previous vigorous cautery
because of an abnormal Pap smear? Is there a history of drug abuse,
since various drugs can lead to amenorrhea, including cocaine, oral
contraceptives, progestin-only pills, calcium channel blockers,
cimetidine, phenothiazines, tricyclic antidepressants, metoclopramide,
and others.
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Table 18. Causes of hirsutism and virililization in females

Increased androgen-dependent hair andvirilism
Genetic and familial increased androgen sensitivity
Androgen excess
"Psychogenic" hirsutism
Stress

Schizophrenia
Exogenous androgens
Medical
Hypoplastic anemias
Growth stimulation
Adrenal replacement
Danazol
Synthetic progestins inoral contraceptives
Adrenocorticotropic hormone (ACTH) therapy
Nonmedical
Bodybuilding and athletic anabolic steroids
Female to male transsexualism
Environmental(?)
Skin contact with male using topical testosterone
Anabolic steroids given to livestock
Plant or microorganism androgens
Adrenal androgens
Congenital adrenal hyperplasias
21-hydroxylase deficiency
Classic
Late-onset
3-β hydroxysteroid dehydrogenase deficiency
Classic
Late-onset
11β-hydroxy lase deficiency
Classic
Late-onset
Adrenal tumors
Adrenocortical carcinoma
Testosterone-secreting adenoma
Adrenal rest adenoma and carcinoma
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Cushing's disease
Ovarian androgens
Polycystic ovary syndrome (PCOS)
Conditions associated with PCOS
PCOS with ovarian tumor
Pineal gland hyperplasia and diabetes
Congenital lipoatrophic diabetes
Hyperprolactinemia
Hyperthyroidism
Hypothyroidism
Androgen-secreting cysts and hyperplasias
Stromal hyperplasia and hypcrtheocosis
Solitary follicle cyst
Hyperreaction luteinalis of pregnancy
Androgen-secreting ovarian tumors
Arrhenoblastoma (androblastoma)
Thecoma-fibroma group tw11ors
Granulosa cell tumors
Lipoid cell rumors
Gyoandroblastorna
Epithelial tumor
Luteoma of pregnancy
Testicular androgens in XY females
5-α reductase deficiency
Mixed gonadal dysgenesis
True hermaphroditism
17-β bydroxysteroid dehydrogenase deficiency
Other rare intersex conditions
Source: Reprinted with permission from: Greydanus DE, Shearin RB.
Adolescent sexuality and gynecology. Philadelphia. PA: Lea & Febiger,
1990:176.

350

Donald E.Greydanus, Hatim A.Omar, Artemis K.Tsitsika etal.
Table 19.Disorders to be distinguished from hyperangrogenism
Hirsutism
Generalized hypertrichosis
Idopathic
Familial
Drugs and toxins
Diphenylhydantoin
Minoxidil
Diazoxide
Phenothiazines
Cyclosporine
Hexacblorobenzene poisoning
Streptomycin
Penicillaroine
Cobalt
Acrodynia
Danazol
Rare genetic syndromes
Hypertrichosis lanuginosa or universalis
Hepatic and erythropoietic porphyrias
Laurence-Moon-Biedl syndrome
Morgagni-Stewart-Morel syndrome
Seckel bird-headed dwarfism
Cornelia deLange's syndrome
Trisomy E
Hurler's syndrome
Chronic systemic illness
Chronic renal failure
Dermatomyositis
Cancer
Chronic central nervous system dysfunction
Cerebral palsy
Spina bifida
Multiple sclerosis
Postencephalitic slates
Others
Endocrine Disorders
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Hypothyroidism
Growth hormone-secreting pituitary adenoma
Hyperprolactinemia
Hirsutism
Generalized hypertrichosis
Chronic malnutrition
Anorexia nervosa
Localized hirsutism or hypertrichosis
Hairy nevus (several types)
Broken extremity bone
Extremity lymphedema
Repeated local trauma
Clitoromegaly without ambiguity
Clitoral priapism
Pibroma of clitoris
Chronic vulvovaginitis
Acne
Cushing's syndrome
Exogenous exacerbating agents
Androgenic steroids
Synthetic progestins
Glucocorticoids
Lithium
Diphenylhydantoin
Barbiturates Isoniazid
Rifampin
Iodides
Kelp and other seaweed
Bromides
Persistent unpleasant body odor without apparent disease
Foreign body (especially in the nose or vagina)
Genetic disorders of organic acid metabolism
Ttimethylaminuria
Dietary spices
Poor hygiene
Source: Reprinted with permission, from: Greydaaus DE, Shearin RB.
Adolescent sexuality and gynecology. Philadelphia: Lea Pebiger, 1990: 177.
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Physical examination
A careful physical examination is important, looking for tall stature (46
XY karyotype), short stature (46,X0 in Turner's syndrome), hypertension
(with delayed sexual maturation as in 17-α-hydroxylase deficiency),
bradycardia (as in hypothyrodism or anorexia nervosa), anosmia
(Kallmann's syndrome), visual field defects with papilledema (brain
tumor), or cachexia (anorexia nervosa) (1,6).
A careful gynecologic examination is important in identifying the
cause of primary amenorrhea. The breast examination may reveal small,
pale areolae (as in anorexia nervosa) or chronic estrogen decrease (as in
Turner's syndrome or other causes of ovarian failure). If amenorrhea is
present with galactorrhea, consider a prolactin-producing pituitary
adenoma. The presence of sparce or absent pubic hair with full breast
development suggests androgen insensitivity syndrome with a 46 XY
karyotype. Youth with hirsutism, severe acne, enlarged clitoris, and scalp
hair thinning (frontotemporal) suggests excess androgen production.
Table 20. Vaginal cytological maturation index
l. Use Pap smear fixative for the vaginal smear
2. One point is given for each superficial cell, 1/2 point for each
intermediate cell, and 0 points for each parabasal cell.
3. A score > 40 suggests some estrogen effect
4. A score of 50-60 is found in pubertal females
5. 0-30 is seen in prepubertal females
6. 31-55 ref1ects a hypoestrogenic state of adult females
Examine the external genitalia and look for an enlarged clitoris
(androgen excess), an abnormal hymen (imperforate or cribriform), or
evidence of estrogen deficiency (thin, pink, vulvar mucosae). Look at the
cervical mucus and evaluate the Vaginal Cytological Maturation Index
(see table 20). If there is copious, watery mucus that reveals spinnbarkeit
by ferning an air-dried slide using microscopy, this suggests a highestrogen state as noted in the late proliferative state before ovulation. A
thick and tenacious cervical mucus that dries in amorphous clumps
without ferning on microscopy suggests a progestin effect as seen in the
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secretory state after ovulation, pregnancy, or due to a progestincontaining pill.
Look for a transverse vaginal septum and presence of a cervix during
the pelvic examination. If there is a history of primary amenorrhea,
establish vaginal patency with moistened cotton or dacron-tipped
applicator or a moistened gloved finger. If a bimanual exam is possible,
look for a mass (consider pregnancy or hematometra); also look for
ovarian enlargement, as in polycystic ovary syndrome. A rectal exam
may be necessary to help establish the presence of a cervix or find a mass
proximal to an obstructed vaginal canal (as in a hematocolpos).
Detection of anatomical genital defects results from genital
inspection and pelvic/rectal examination. A karyotype is of1en needed in
cases of primary amenorrhea. Definitive procedures include sonography,
MRI, and laparoscopy. The patient should be screened for additional or
associated congenital anomalies if a genital anomaly is present; these
include musculoskeletal, cardiac, and/or renal anomalies in some cases.
Endocrinological and gynecological consultation is often necessary for
those with primary amenorrhea. Tables 21 and 22 outline basic
laboratory testing for adolescents with amenorrhea.

Mayer-Rokitansky-Küster-Hanser Syndrome
(MRKH Syndrome)
The MRKH syndrome (see table 22) or Müllerian agenesis is a
congenital condition in which there is absence of all or part of the uterus
and vagina as the cause of primary amenorrhea (1). Typically there is
uterine agenesis (or rudimentary uterine development) with absence of
the upper two-thirds of the vagina in association with the presence of
ovaries, fallopian tubes, breasts, pubic hair, normal female hormonal
patterns, and a normal female karyotype (46, XX). Over half may have
urinary tract anomalies while 25% have vertebral column malformations.
The differential diagnosis includes the androgen insensi1ivity syndrome
(see table 22) and confirmatory diagnostic tests include the pelvic
ultrasound, MRI, and laparoscopy.
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Table 21. Laboratory Testing for Amenorrhea in Adolescents (to
be used selectively after thorough clinical examination)
Pregnancy Test
Hormonal investigation:
LH & FSH: Increased inovarian failure/dysgenesis; normal or
decreased inothers
Thyroid hormone levels
Prolactin levels
If virilization/hirsutism present: DHEAS, LHJFSH ratio
(nl:<2.5: 1), testosterone (total and free)
Level of estradiol & progesterone and/or
Vaginal smear to evaluate for epithelial cell estrogenization
Pelvic ultrasound to define anatomy (uterine hypoplasia)
Vaginoscopy
Bone age
Chromosome evaluation
Anti-ovarian antibodies
Head CT/MRI
Pelvic/abdominal MRI
Renal ultrasound/IVP
Laparoscopy

Other vaginal outflow tract abnormalities
The female with an imperforate hymen is noted in 1 in 1,000 and
presents with primary amenorrhea and cyclic pelvic pain. There is a
bulging, bluish hymenal membrane and even retrograde menses that may
predispose to endometriosis. Management involves early diagnosis with
incision and drainage of the imperforate hymen under anesthesia (72,73).
Transverse vaginal sepum is noted in 1 in 80,000 and the obstruction is
due to a septum at the junction of the upper and middle thirds of the
vagina. Retrograde menstruation may occur, leading to endometriosis.
Similar problems can occur with longitudinal vaginal septum, when the
septum is attached to the vaginal wall on the side of the cervix, thus
obstructing outflow.

Table 22. Gynecological disorders of adolescent females
Gynecologic
disorder

Special comments

Differential diagnosis

Laboratory
testing

Amenorrhea
(Primary)

Physiologic is the main cause;
MRKH syndrome assoc. with
Renal abnormalities and Spinal
malfomrations.
Short stature with delayed sexual maturation:
Turner syndrome; delayed sexual maturation
+ hypertension seen in 17-α-hydroxylase
deficiency; Swyer syndrome; absencc of
smell sense suggests Kallmann syndrome;
visual field deficits suggests brain tumuor.

Serum
gonodotropins
(FSH, LH), prolactin,
TSH:
Pelvic Ultrasound MRI,
Head CT/MRI Renal
ultrasound/IVP
(intravenous pyelogram:
Karyotype
Laparoscopy

Amenorthea
(secondary)

Pregnancy is the main cause: history of
sexual activity- may present with a midline
"pelvic mass"; causes of oligomrnorrhea and
secondary amenorrhea are essentially the
same. A1so important is history of dietary
habits, exercise, stress: acne and hirsutism
suggest elevated androgen levels; Athlete
Triad Syndrome: amenorrhea, dysfunctional
eating patterns, osteopenia-porosis.

Physiologic
Imperforate: hymen
Mayer-Rokitansky-Kuster-Hauser (MRKH)
Syndrome;
Turner syndrome (45,XO and mosaicism)
Chronic Illness
Hypothalamic: Stress. eating disorders, e.xe:rcise,
depression;
Androgen insensitivity syndrome (46 XY); Swyer
syndrome; others: See Text
Pregnancy; lactation;
Stress, eating disorders,
Chronic illness,
Exercise induced,
prolactinoma (headaches, visual field deficits.
galactorrhea)
PCOS (polycystic ovary syndrome);
See text.

Dysmcnorrhea
(Primary)

Pelvic pain during normal
ovulatory menstruation; no underlying pelvic
pathology.
May also see gastrointestinal symptoms.

Physiologic

Pregnancy
Test (β-hCG)
Progesterone challenge
Serum estrogen, FSH, LH:
bone mineral
densitometry:
Serum prolactin
Thyroid screen;
Head CT

headache, myalgia, sweating.
Dysmenorrhea
(Secondary)

May be seen at menarche or 3+ years postmenarche.

Endometriosis
Pelvic lnflammatory Disease
Reproductive tract anomalies
Pelvic adhesions
Cervical stenosis
Ovarian masses
Pelvic congestion syndrome
Rule out Urinary Tract or
Gastrointestinal causes
Anovulatory bleeding;
Pregnancy, ectopic pregnancy; coagulation
disorders (as von Willebrand disease, others),
anatomic lesions, endometrial
pathology; cervicitis or cervical dysplasia; pelvic
inflammatory disease; ovarian cysts; polycystic
ovary syndrome: severe stress, tapid or severe
weight gain or loss, drug abuse; see text.

laparoscopy
STD screen
Pelvic Ultrasound; MRI

CBC, platelets, betaHCG, Pap smear, PT,
PTT, bleeding time,
other coagulation
disorders screening; D2 l progesterone; thyroid
screen: S'TD screen;
ultrasound (transvaginal;
pelvic), MRI;
hysterosoopy.
β-hCG; pelvic
ultrasound

Dysfunctional
Uterine
Bleeding
(DUB)

Menstrual calendar useful to get accurate
history of rnenstrual pattern; get sexual
activity history;
Establish presence/absence of ovulation:
basal body temperature charts, serum
progesterone, urinary luteinizing hormone
(LH) and possibly endometrial biopsy.
role out an STD: virilization evaluation
necessary if hirsutism present.

Ectopic
Pregnancy

Pain with history of secondary amenorrhea
often with vaginal bleeding.

See DUB differential

Endometriosis

Presentation in adolescence not the same as in
adults. May have acyclic pain, abnormal
uterine bleeding. GI symptomatology
Pain associated with ovulation in the middle
of a menstrual cycle. May last 1-3 days and

See secondary dysmenorrhea

Laparoscopy
Laparotomy

See secondary dysmenorrhea

Menstrual calendar

Mittelschmertz

Ovarian Masses

Pelvic.
lnflammatory
Disease

be mild to severe.
Presents with a lateral location; abnormal
menses

STD that can lead to uterine tenderness,
adnexal tenderness, tenderness on cervical
motion, muco-purulent vaginal or cervical
discharge; can see fever (T > 101 F, 38.3 C);
polymicrobial disorder of the upper genital
tract often precipitated by Neisseria
gonorrhoeae, Chlamydia trachomatis, others
(Gardnerella vaginalis, Mycoplasma hominis,
Ureaplasma urealyticum, Haemophilus
influenzae, coliforrns, cytomegalovirus,
peptostreptococcus, and other anaerobes).

Ovarian cysts
Ovarian tumors (benign, malignant)
Polycystic ovary syndrome
Ectopic Pregnancy
Tubo-ovarian mass
Ectopic pregnancy, appendicitis, pyelonephritis,
ovarian cyst, septic abortion, others.

Can involve various combinations of
endometritis, salpingitis, tubo-ovarian
abscess, and pelvic peritonitis. Complications
include infertility, chronic pelvic pain.
ectopic pregnancy.

Polycystic ovary

Insulin resistance with hyperinsulinemia.

Other causes of hyperandrogenism; HAIR-AN

Pregnancy test
Pelvic Ultrasound

Non-specific:
white blood cells on
saline prep; elevated
ESR; elevated CRP: lab
evidence of Neisseria
gonorrhoeae or
Chlamydia trachomatis;
Specific Criteria
Positive biopsy:
Endometrium
showing
endometritis;
Evidence of PID
on laparoscopy;
ultrasound or
MRl showing
that fallopian
tubes are thick and
filled with fluid;
may be free fluid
in the pelvis or a
tubo-ovarian
complex.
LH, FSH, T-4, prolactin,

syndrome (PCOS;
hyperandrogenemia
syndrome

hyperandrogenemia, and chronic anovulation; can
see irregular menses (secondary amenorrhea,
oligomenorrhea, DUB),
hirsutism, possible virilization, variable
obesity, acanthosis nigricans, possible
bi1ateral enlarged ovaries.

Syndrome; Congenital adrenal hyperplasia (11Bhydroxylase,
21-hydroxylase, 3B-hydroxysteroid dehydrogenase
deficiency); Cushing's disease, hyperprolactinemia,
Ovarian or adrenal tumor: Mixed gonadal
dysgenesis (4SX/46XY, 4SX/46XX/46XY):
Gonadal dysgenesis with virilization; true
hermaphroditism

testosterone (total and
free), insulin level; lipid
profile:
dehydroepiandrosterone
sulfate (DHEAS): 17-αhydroxyprogesterone;
24 hour urine for free
cortisol; dexamethasone
suppression test; Pelvic
ultrasound

Premenstrual
Syndrome
(PMS)

Variety of symptoms start before and end
with menses

Premenstrual dysphoric disorder (PMDD);
depression; anxiety; others, depending on the
presenting symptoms; see text.

DSM-IV (2000) criteria
for PMDD

Abbreviations: CBC: complete blood count; Pap, Papanicolaou smear; STD: sexually transmitted disease; MRI: magnetic resonance
imaging; GI, gastrointestinal; ESR, erythrocyte sedimentation rate; F; Fahrenheit; C: Centigrade; HAIR-AN: hyperandrogenism,
hirsutism, insulin resistance, acanthosis nigricans; DSM-IV: Diagnostic Statistical Manual-4th Edition (American Psychiatric
Association); PT: prothrombin time; PTT: partial thromboplastin time. Reprinted with permission from Greydanus DE.
Feinberg AR, Patel DR, Homnick DN,eds. The Pediatric Diagnostic Examination. New York: McGraw-Hill, 2008.
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Others
In male pseudohermaphroditism there is a 46 XY karyotype and a female
phenotype with uterovaginal atresia and functioning testicular tissue.
Leydig cell agenesis occurs due to defective LH receptors and this leads to
inadequate androgen secretion. Various autosomal-recessive disorders are
noted with ambiguous genitalia. In 17 -a-hydroxy lase deficiency, there
is an individual with a female phenotype that has breast tissue,
primary amenorrhea, and often, hypertension.
In the androgen insensitivity syndrome (formerly called the testicular
feminization syndrome), the individual has a female phenotype with full
breast development and scant or absent pubic and axillary hair. The
vagina ends in a blind pouch and testes are present. There is typically a
history of a herniorrhaphy as an infant. There is also an increased level of
LH, testosterone, and estradiol; this individual is at increased risk for a
gonadal neoplasm, though this risk is lower than that seen in 46
XY gonadal dysgenesis.

SECONDARY AMENORRHEA
The most common underlying cause of secondary amenorrhea (after
pregnancy) in an adolescent is anovulation, resulting from inhibition of
FSH and LH because of various factors that influence the hypothalamus
(see table 22) (1,6,9,69,74). This "hypothalamic" amenorrhea can be due
to major weight loss or gain, increased stress, systemic illness, excessive
physical activity as noted in competitive sports, and others. Secretion of
steroid and neuroendocrinc hormones can resemble patterns noted in
early puberty or even pre-puberty with low gonadotropin levels and
reduced sex hormones (androgens and estrogen).
Other factors inducing amenorrhea include pregnancy, immaturity,
thyroid disorders (hyper or hypothyroidism), polycystic ovarian disorder,
anorexia nervosa (even before severe weight loss develops), other
chronic illnesses, various medications, illicit drugs, prolactinoma,
pituitary destruction from infiltration or infarction, Asherman's
syndrome (uterine synechiae) and others (sec table 22).
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As noted, overlap and confusion between causes of p1imary versus
secondary amenorrhea may occur, since both can be due to dysfunction of
the hypothalamic-pituitary-ovarian axis. The history of previous
menstruation suggests the presence of a patent uterus and vagina, thus
eliminating the diagnosis of a congenital anatomic disorder of the uterus
and/or vagina (i.e, Mayer-Rokitansky-Kuster-Hauser syndrome). Causes
of secondary amenorrhea and oligomenorrhea are essentially the same.
Table 23 provides a suggested plan for evaluating the cause of secondary
amenorrhea (see table 23 and figure 3). Table 24 provides a plan for
evaluation of an ovarian versus adrenal etiology in an adolescent with
hyperandrogenism and oligomenorrhea or amenorrhea.
Table 23. Plan for evaluation of secondary amenorrhea
Pregnancy should always be considered and ruled out, even with denial
of sexual activity and history of only one late or absent menstrual
period.
The state of estrogenization should be determined and determine if

estrogen priming of the endometrium is occurring using the vaginal
cytologic maturation index (see table 20). Look at microscopic
evidence of ferning (denoting anovulation) in an air-dried slide of
cervical mucus.

Consider a progestin challenge. If there is no pregnancy or chronic
illness present, give medroxyprogesterone acetate, 10-20 mg/day, PO,
for 5 days, or a single dose of progesterone-in-oil, 100 mg, IM. If a
withdrawal bleeding occurs, this suggests the hypothalamic-pituitary
axis is able to respond, at least to some extent, there is an
endometrium, and the genital outflow tract is patent. The usual
situation is either hypothalamic suppression or reversible chronic
anovulation. Mild hypoestrogenism is suggested by a scant bleeding while
no bleeding at all suggests such conditions as outflow-tract
agenesis or obstruction, loss of the endometrium, ovarian failure, or
chronic hypoestrogenism from various causes. The presence of chronic
hypoestrogenism implies the need for estrogen replacement. If there is a
non-response along with the presence of normal or low FSH, this
suggests major dysfunction of the hypothalamic-pituitary axis.
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If the patient has normal estrogenization and normal withdrawal
bleeding with the progestin challenge, the patienl and parents can be
reassured that the reproductive tract is normal. Help her deal with such
underlying factors as stress, extreme exercise, major weight gain or
loss and others. If the rest of the evaluation is normal, one can adapt a
"watch and wait" process in which the patient is seen periodically (as
every 3-6 months) to await the resumption of normal menstruation. A
repeat or periodic progestin challenge test may be helpful in select
situations; it may also prevent endometrial proliferation secondary to
unopposed estrogen that may lead to dysfunctional uterine bleeding (as
menometrorrhagia). Oral contraceptives may be used without fear that
they will delay the resumption of normal menstruation when stopped.
Oral contraceptives can also be used to manage dysfunctional uterine
bleeding if this develops.
Oligomenorrhea is a common process in adolescent females and
extensive evaluation is not usually needed in an otherwise healthy
patieot who is within 2 years of her menarche. Specific evaluation may
proceed, however, if the oligomenorrhea continues over 2 years from
menarche, develops for over 6 months in a youth with previous normal
menses, or if the initial evaluation suggests an underlying chronic
illness.
If the cause of the amenorrhea or oligomenorrhea is not clear after the
above evaluation, a more extensive evaluation is necessary looking for
various medical conditions and/or mental health issues (i.e., stress) that
starts with a full history and complete physical examination. The
evaluation includes pelvic and rectal exams looking for potential
anatomical or physiologic disorders (Tables 15-19). It is very important
to identify the presence or absence of uterine or adnexal mass(es). A
pelvic ultrasound and MRI may be necessary to confirm normal or
abnormal anatomy while important laboratory data supportive of the
evaluation are noted in table 21. A head CT or MRI may be needed to
rule out a CNS tumor especially if galactorrhea or various neurological
signs are present
Look for hyper/hypothyroidism and galactorrhea. An abnormal TSH
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screen should prompt further evaluation for thyroid dysfunction that
can lead to altered menstrual status. Increased prolactin levels suggest
hyperprolactinemia as the cause of the menstrual dysfunction, though
increased prolactin can also be seenn in hypothyroidism, hirsutism, and
PCOS as well. Fasting prolactin levels can be increased without
galactorrhea being present Prolactin levels over 50-100 ng/rnl warrant
a head MRI or CT to screen for a prolactinoma. Prolactin levels over
70 mg/ml are typically seen with amenorrhea, though screening for
chronic renal failure should also be done. Low levels of serum
prolactin in cases of amenorrhea are consistent with hypothalamic
disorder induced by stress.
It is also important to evaluate this patient with .secondary amenorrhea
for dysfunction of the hypothalamic-pituitary-ovarian axis. An FSH
and LH level can be obtained for perfoming the progestin challenge
test, though some clinicians will not perform this screen unless there is
no withdrawal bleed after the progestin is given. Since the added
progestin can suppress the gonadotropins, one should wail at least 7 to
10 days after the progestin challenge test to screen for levels of FSH
and LH. If the FSH is over 40 mlU/L, and the LH is over 25 mlU/L,
this indicatcs a hypergonadotropic condition suggesting the presence of
ovarian failure essentially in proportion to the degree of FSH/LH
increase; further evaluation is necessary, as reviewed below.
It is also important to obtain a karyotype in these patients, looking for such
conditions as 46,XY or 45,X or 45.X/46,XX. If a 46 XY
karyotype is found, perform a laparoscopy while an autoimmune
disease evaluation is important to pursue if 45,X/46,XX is found
(46XY could be the diagnosis in primary, not secondary ameonorrhea).
It is often difficult to separate low from normal FSH/LH levels,
particularly in young adolescents. However, low or normal
gonadotropin levels in the presence of a normal progestin challenge
suggest a diagnosis of reversible hypothalamic dysfunction with
anovulatiou, due to stress or early PCOS. Gonadotropin levels that are
unmeasurable suggest irreversible deficiency of the hypothalamus or
the pituitary. Low or normal gonadotropin levels in the presence or
absence of a withdrawal bleed suggest an underlying endocrinologic
disorder of either hypothalamic or pituitary origin. Consider PCOS if
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the LH is increased and the FSH is normal or low; however, in some
PCOS, the LH is also normal. An elevated LH in contrast to the
FSH level is also found in hyperestrogenism. If the patient with
amenorrhea bas normal estrogen status, this suggests that the ovaries
are functional. Low estrogen levels are consistent with ovarian failure
if there is also high FSH/LH or pituitary deficiency with low FSH/LH.
If hypothalamic dysfunction occurs, the estradiol levels may be near the
lower margin of normal with low FSH/LH levels. Estradiol levels can be
mildly increased or normal in PCOS or other conditions of
hyperandrogenism. If hirsutism is noted, screening for hyperandrogen
states is necessary, as reviewed in the text
If oligomenorrhea or amenorrhea develops in the presence of a
hyperandrogenic state, evaluate for an ovarian versus adrenal etiology, as
reviewed in table 24.
Perplexing causes of amenorrhea in youth may require consultation
with experts in endocrinology, gynecology, or neurology. Management
depends on the underlying cause and is reviewed below. If transient
hypothalamic suppression is found, reassurance and patience is the usual
recommendation. It is important to consider various factors that influence
menses (see table 25). If systemic disorders (including endocrine conditions)
or tumors are found, again, referral to appropriate specialists is needed.
Polycystic ovarian syndrome (PCOS) is reviewed below. If there is primary
failure of the ovaries, hormonal replacement is needed, as reviewed below.
Comment is now provided on specific medical causes of amenorrhea.

HYPOTHALAMIC AMENORRHEA
Hypothalamic disorders causing amenorrhea include constitutional
growth delay, congenital GnRH deficiency, and hypothalamic
amenorrhea (1,9). Congenital GnRH deficiency can be seen in the
Kallman syndrome with hypogonadism and anosmia. Hypothalamic
amenorrhea results from such causes as psychological stress, poor
nutrition, chronic illness, and strenuous exercise. The amenorrhea is due
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to disruption of GnRH pulsatile release that leads to reduced levels of
FSH, LH, estradiol, and prolactin along with bypercortisolism. Stress that
can induce amenorrhea can include depression, anxiety, and illicit drug
use or withdrawal from drug use. Pseudocyesis (false pregnancy) is an
extreme example in which LH and prolactin secretion are high enough to
sustain luteal function and even galactorrhea. The inhibition of
hypothalamic neuroendocrine function seen in systemic illness (see table
26) is similar to that described in starvation along with additive factors of
stress and altered steroid metabolism.
Menstrual dysfunction may be seen in female adolescents with obesity
because of chronic anovulation. The underlying mechanisms of the
oligomenorrhea and secondary amenorrhea include increased estrogen
levels because of aromatization of androgens from excess
adipose tissue; in addition, there is complex interplay of hyperinsulinism
and hyperandrogeuism, more characteristically seen in PCOS, but seen to
some extent in obesity. Stress noted in some with obesity, can also
contribute to menstrual disruption. Anovulation and obesity can also be
secondary to underlying hypothalamic disruption seen in the Prader-Willi
syndrome or hypothyroidism. If the obese individual has no underlying
medical illnesses, weight loss can lead to restoration of menstruation.

ANOREXIA NERVOSA
Menstrual irregularities can develop in females with eating disorders,
such as anorexia nervosa and bulimia nervosa (1,9,75-77). Amenorrhea
may develop with or preceed significant weight loss in the female with
anorexia nervosa and menstruation may not return until after the weight
has been normalized. Estrogen deficiency along with low calcium dietary
intake often leads to osteopenia or even osteoporosis in these patients.
Given that adolescence is the age during which peak bone mass is
acquired, there may be severe consequences for future bone health. Bone
densitometry should always be part of the evaluation; calcium
supplementation and in some cases OCP's can be used until weight
normalization and stabilization occurs (see below text on the female
athlete triad) (78).

Menstrual Disorders in Adolescent Females

365

Trial
medroxyprogesterone,
10 mg x 10 days
+/Withdrawal,
Refer for
treatment

+
Withdrawal,
normal labs

Withdrawal,
LH/FSH,
estradiol

Treat or refer
appropriately
Consider evaluation
for

Menstrual calendar
Reevaluate in 1-3

Abnormal
cycles

Normal cycles
Menstrual calendar
Reevaluate in 13 months

Used and adapted with permission from: Joffe A, Blythe MJ. Handbook of
adolescent medicine. Adolesc Med 2003;14(2):296, figure 2; Greenfield TP.
Blythe Ml. Menstrual disorders in adolescents» In: Greydanus DE, Patel
DR, Pratt HD, eds. Essential adolescent medicine. New York, McGraw-Hill,
2006:600.
Figure 3. Evaluation of secondary amenorrhea and oligomenorrhea in the
adolescent patient.
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OTHER HYPOTHALAMIC AND PITUITARY DISORDERS
Hypogonadotropic anovulatory amenorrhea can develop because of
hypothalamic destruction by infarction, tumor infiltration, or trauma
(1,9). Though amenorrhea may be the initial or presenting complaint,
neurological symptoms and/or evidence of other hormone deficiencies
may be seen, together with low levels of gonadotropins (FSH, LH) and
end-organ hormones (estrogen, testosterone).
Signs of estrogen
deficiency are typically less evident than that seen with primary ovarian
failure.

Table 24. Evaluation of ovarian versus adrenal etiology in an
adolescent with hyperandrogenism and oligomenorrhea
or amenorrhea*
Measure the scrum or plasma testosterone, free testosterone, and
androstenedione.
In functional ovarian or adrenal hyperandrogenism, the total
testosterone may be normal but the free testosterone and androstenedione
are increased. If the total testosterone is over 200 ng/dL, suspect an
ovarian or adrenal virilizing tumor and obtain imaging studies.
Measure the DHEAS. If the levels arc over 600 µ/dL, suspect an adrenal
rumor and obtain imaging studies.
If the etiology remains unclear, obtain a dexamethasone suppression test.
using an oral dose of 1 mg/m2 daily in divided doses for 5.7 days,
Measure the plasma free testosterone, DHEAS and cortisol both before
and after administration:
Suspect PCOS if the free testosterone is not suppressed, but the cortisol
and DHEAS are.
If neither the free testosterone nor the cortisol is suppressed, consider:
an adrenal virilizing tumor, Cushing's syndrome, or noncompliance.
If the free testosterone is normally suppressed. then obtain an ACTH
stimulation test to rule out congenital adrenal hyperplasia (CAH).
Abbreviations: DHEAS= dihydroepiandrosterone sulfate; PCOS = polycystic ovary
•
syndrome; ACTH = adrenocorticotropic hormone.
*Reprinted, with permission, from; Greydanus DE. Breast and gynecological
disorders. In: Hofmann AD, Greydanus DE, eds. Adolescent medicine, 3rd ed.
Stamford. CT: Appleton Lange. 1997:541.
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Table 25. Influences on the menstrual cycle

Age
Weight and Height
Physiologic and sex development
Psychological stress
Nutritional deficiencies
Genetic predisposition
Percent body fat
Amount of exercise
Chronic Illness
Medications (prescription or over the counter)
Race
Others
Table 26. Chronic illnesses that induce hypothalamic amenorrhea
Cancer (including chemotherapy and radiation)
Celiac Disease
Chronic renal failure
Cystic fibrosis
Diabetes mellitus (poorly controlled)
Inflammatory bowel disease
(Growth issues and amenorrhea may arise before bowel symptoms)
Sarcoidosis
Sickle cell disease
Systemic lupus erythematosus (other rheumatoid disorders)
Thyroid disease
Tuberculosis
Other systemic illnesses
If gonadotropins are very low (i.e., <10 IU/L), image the sella turcica
to look for a lesion of the anterior pituitary or hypothalamus causing the
amenorrhea. Trauma or tumor can cause disruption of the pituitary stalk
resulting in pubertal disruption including growth delay; if this occurs
after puberty is finalized, findings include amenorrhea, galactorrhea,
diabetes insipidus, hypoadrenalism, and hypothyroidism.
The most
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common tumor that is involved is a craniopharyngioma that can present
with headaches, visual field defects, and dysfunction of the
hypothalamus. A head MRI or CT will identity the tumor.
The most common infiltrative disorders of the hypothalamicpituitary area are central nervous system leukemia and histiocytosis X;
others include tuberculosis, sarcoidosis, head trauma, hemochromatosis,
and postpartum necrosis. With the exception of craniopbaryngiomas,
intraspinal tumors cause headaches and abnormal neurological findings
more often than they do amenorrhea. Also, craniospinal irradiation for
cancer can lead to hypothalamic-pituitary dysfunction. The empty sella
syndrome has rarely been noted in adolescents. Prolactin levels should be
measured in chronic menstrual dysfunction, especially if galactorrhea
develops. Prolactin secretion disorders arc noted in 15% of adult females
with amenorrhea. and the degree of elevated prolactin is associated with
the degree of menstrual dysfunction. Prolactin levels over 70 ng/L are
associated with amenorrhea, though the amenorrhea is not related to the
presence or severity of galactorrhea.

PRIMARY AND SECONDARY OVARIAN FAILURE
Increased FSH and LH levels are noted in hypergonadotropic
hypogonadism as reflected in the ovarian failure of gonadal dysgenesis
(Turner Syndrome) (79-82) effects of radiation or chemotherapy, and
autoimmune oophoritis (1,3,9). Approximately 25% of females with
primary amenorrhea have gonadal dysgenesis. Those with the 45,XO
karyotype have classic features, including short stature and
hypoestrngenism with failure of secondary sexual development (see table
27). The 45,X/46,XX karyotype may have few somatic defects other than
short stature, and their ovaries may allow ovulation and pregnancy prior
to ovarian failure.
The development of amenorrhea and loss of estrogenization after a
few or some menstrual cycles also occurs in ovarian failure due to
irradiation or chemotherapy (i.e., vincristine, cyclophosphamide, others)
for management of cancer and also in the rare situation of premature
menopause. The combination of both chemotherapy and radiation is
especially toxic to ovarian function. Premature menopause may occur as
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a feature of an autoimmune, multiple endocrine syndrome with
antiovarian antibodies or even as an isolated disorder. It may also be seen
in resistant ovary syndrome, as well as with various collagen vascular
disorders or autoimmune endocrinopathies, such as diabetes mellitus,
myasthenia gravis, hyperparathyroidism, thyroiditis, Addison disease,
pernicious anemia, or vitiligo. Management of ovarian failure includes
hormone replacement (estrogen and progesterone) along with
counseling about self-image, infertility, and sexual functioning (81,82).
Table 27. Features of Turner syndrome*
Short stature (usually does not exceed 142 cm)
Sexual infantilism with streak ovaries (may have slight amount of
pubic hair)
Turner facies (fish mouth, low-set ears. malformed ear lobes,
epicanthal folds, micrognathia)
Short, webbed neck with low hairline
Cubitus valgus (wide carrying angle of forearm)
Fingernail anomalies
Shield chest with broadly spaced, hypoplastic nipples
Abnormal hearing and vision (including color blindness)
Cardiovascular disorders (hypertension, coarctation of the aorta,
aortic stenosis, bicuspid aortic valve)
Various renal anomalies
Multiple pigmented nevi
Associated with recurrent otitis media, diabetes mellitus, chronic
lynmphocytic thyroiditis
Features in infancy: short birth length, 1ymphedema of hands and feet,
loose posterior neck folds
Hirsutism if component of the Y chromosome is present
*Reprinted, with permission, from: Greydanus DE. Breast and gynecological
disorders. In: Hofmann AD, Greydanus DE, eds. Adolescent medicine. 3rd
ed. Stamford, CT: Appleton Lange, 1997:339.
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ENDOCRINE DISORDERS
Excessive production or major deficiency of the major hormones may lead to
significant disruption of the complex menstrual cycle either
because of interference with neuroendocrine feedback and/or negative
impact on the overall health of the adolescent female (1,3,9). This
hypothalamic dysfunction can lead to anovulation with dysfunctional
uterine bleeding or amenorrhea. Thus, menstrual dysfunction can be seen
in such endocrine disorders as hyperthyroidism, hypothyroidism,
Addison disease, Cushing syndrome, late-onset congenital adrenal
hyperplasia (21-hydroxylase deficiency), hyperprolactinemia, PraderWilli syndrome, Laurence-Mood-Biedl syndrome and others.
Amenorrhea is typically seen with hypothyroidism, while
dysfunctional uterine bleeding (DUB) is often noted with
hyperthyroidism. Hyperpigmented skin folds and pressure areas are seen
in Addison Disease and vitiligo is found with ovarian autoimmune
disease. Acanthosis nigricans reflects insulin resistance and androgen
excess is seen with anovulation and menstrual dysfunction; the latter is
noted with polycystic ovary syndrome (PCOS--see next section).
Menstrual dysfunction can also be seen with pituitary adenomas. If
growth hormone excess starts in childhood, an acromegalic tall stature
results and later onset leads to acromegalic features of enlarged jaws and
digits; acromegaly is typically seen with hyperprolactinemia. Rare tumors of
the ovary or liver can produce human chorionic gonadotropin
leading to menstrual dysfunction.

POLYCYSTIC OVARY SYNDROME (PCOS)
PCOS pathophysiology
PCOS (PCO; hyperandrogenemia syndrome; old term: Stein-Leventhal
syndrome) is a hyperestrogenic, hyperandrogenic state of anovulation
found in 5%-10% of adolescent and adult females, representing 30% of
adult women with chronic amenonorrhea and 75% with chronic
oligomenorrhea
(see table 22) (1,6,83-87).
underlying
The
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pathophysiology of PCOS is chronic dysfunction of hypothalamic
stimulation of the pituitary, pituitary stimulation of the ovaries, and
steroid feedback to the hypothalamus. There seems to be an increase
GnRH that induces rhe pituitary to increase LH secretion (both basal
levels and pulse amplitude), eithet as a cause or result of androgen
synthesis from the ovaries.
Hyperinsulinemia is part of PCOS and may also induce increased
LH secretion (88). PCOS patients, whether obese or not, have increased
levels of insulin in comparison to controls. The stale of insulin resistance
found in PCOS patients leads to a state of byperinsulinism that induces
increased androgens in hyperandrogenic females but not normal females.
There is resistance to the normal hypoglycemic effect of insulin. This
resistance is found in muscle and adipose tissue, but not in liver tissue.
When puberty begins, the anterior pituitary reacts to increased
estrogen levels by increasing LH levels and decreasing FSH production
that lead to abnormal stimulation of ovarian-derived estradiol and
androgens as well as abnormal maturation of ovarian follicles and a state
of chronic anovulation. The anovulation leads to the prevention of
cyclical progesterone secretion. Since there is less FSH secretion, antral
follicular development is dysfunctional, oocyte degeneration increases,
and ovulation does not occur.
There is excess secretion of androgens that is mainly ovarian. In
normal situations, progesterone is changed in the ovaries to 17-αhydroxyprogesterone and chen to androstenedione in ovarian theca cells
by 17-α-hydroxylase and 17,20-lyase. This androstenedione is converted
to testosterone in theca cells and then estradiol in granulosa cells. In
addition, PCOS patients have a congenital defect of cytochrome P450l7-α-hydroxylase that leads to an increase in 17-α-hydroxylase and some
increase in 17,20-lyase (desmolase) action causing an increase of
testosterone concentration in the ovaries. Many PCOS patients also have
decreased production and levels of sex steroid binding globulin (SSBG),
thus allowing for higher free testosterone levels even if the total
testosterone is normal. There is also heightened androgen production
from the adrenal glands along with heightened peripheral production of
estrone from aodrogens in adipose tissue, leading to increased stetoid
levels in PCOS patients. Premature atresia of follicles and anovulation
result from elevated testosterone levels. The elevated estrone levels
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stimulate GnRH from the hypothalamus leading to increased LH levels and
secretion.
Testosterone
androstenedione
are
androgen
and
metabolized to a potent androgen, DHT (5-α-dihydrotestosterone), in the
skin.
The result of PCOS pathophysiology is a chronic state of high
androgen and estrogen levels, stimulating an increased but acyclical
production of GnRH from the hypothalamus that causes a dysfunctional
cycle of anovulation and hyperandrogenism. Such a PCOS
pathophysiologic state can also occur because of an underlying state of
elevated adrenal androgen production, as in Cushing's syndrome or
congenital adrenal hyperplasia, some ovarian tumors or dysfunctional
release of GnRH from the hypothalamus because of other conditions.
Table 28. Laboratory test results in PCOS patients
LH : Mild increase in levels
FSH: Low limits of normal
LH-f"SH ratio:> 2.5:1
Estradiol: Moderate increase in levels
17-hydroxyprogesterone: mild increase in levels
Prolactin: Mild increase
Androgen: mild to moderate increase in levels
-free and total testosterone
-dehydroepiandrosterone sulfate (DHEAS) (can be normal)
-androstenedione
-early morning urinary 17-ketosteroids
Sex hormone-binding globulin (SHBG): decreased
Hyperinsulinemia (fasting levels of glucose/insulin ratio <4.5)
Abnormal lipid profile
-Increased cholesterol
-Increased low-density lipoprotein
-Increased very-low density lipoprotein
-Reduced high-density lipoprotein
-Increased triglycerides
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PCOS symptomatology
Variable PCOS features (see table 28) may arise in females as or after
puberty begins, including amenorrhea or irregular menstrual bleeding
from anovulation, hirsutism, acne, and obesity. Hyperandrogenism is
reflected by hirsutism (measured with the Ferriman-Gallway scale) in
over 60%, acne vulgaris in 25%, and male-pattern alopecia in some
PCOS patients (l,6,67 ,89,90). Virilization may occur as reflected in
clitoromegaly (over 5 mm in diameter), voice deepening, and abnormal
fat-muscle distribution. There may be premature adrenarche. At puberty,
the patient may be overweight for height and even overtly obese.
Acanthosis nigricans (velvety, hyperpigmented areas, especially in the
axilla, neck and back) may reflect hyperinsulinemia, often associated
with obesity (91). The family history may be positive for PCOS, diabetes
mellitus, hyperinsulinism, hirsutism, infertility, and/or adrenal enzyme
deficiency.
The term, PCOS, represents a spectrum of hyperiosulinemia
syndrome and an adolescent with PCOS may not have all the classic
PCOS features found in adult females. Adolescents with PCOS may have
one or two classic features along with suggestive laboratory findings (see
next section) and later progress to other PCOS features. For example,
there may not be oven obesity or enlarged ovaries until adulthood.
Eventually the ovaries become enlarged with a thickened capsule that
contains many small follicular cysts with tbeca intema hyperplasia
("string of pearls") that is seen on an ultrasound examination. In adults
obesity is noted in over 50% but ovulation may occur in 10% to 20% and
as many as one-quarter may have regular menstrual cycles. Overt
diabetes mellitus (type 2) may develop in some PCOS patients.

PCOS laboratory studies
Classic laboratory results in PCOS patients are listed in tables 22 and 28.
The combination of an increased LH-FSH ratio (>2.5: 1) with increased
free testosterone and androstenedione levels is suggestive of PCOS. A
pelvic examination, pelvic ultrasound, or laparoscopy may identify
polycystic and sometimes enlarged ovaries (bilateral); however, the
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ultrasound in adolescents with PCOS may be non-specific and normal
females may have the appearance of"polycystic" ovaries.
The diagnosis of PCOS in young adolescents may be difficult and
subtle based on general symptomatology along with an increase in
androgens, estradiol (can be normal), a high LH-FSH ratio (>2.5: 1 ), with
or without ultrasound confirmation of polycystic ovaries. A diagnosis of
PCOS may be made if two of these three criteria are present:
oligomenorrhea and/or anovulation, hyperandrogenism (clinical or
biochemical evidence), and ultrasound evidence of polycystic ovaries
(92). This is an expansion (Rotterdam criteria) of a National Institute of
Health (NIH) conference in 1990 that defined PCOS as a disorder with
hyperandrogenism and/or hyperandrogenemia, oligomenorrhea, and
exclusion of known disorders (93). The exact definition with specific criteria
remains controversial, especially for adolescents ( l ,93).
If there is a rapid onset of hirsutism or virilization with high levels of
150-200
testosterone
(>
ng/dl),
DHEAS
(>700µ/dL)
and
androstenedione (>500 mg/dl), consider an adrenal tumor as the
diagnosis. Polycystic ovaries can be seen with Cushing disease,
congenital adrenal hyperplasia (including some partial enzyme
deficiencies), hyperprolactinernia, and HAIR-AN syndrome. The HAIRAN syndrome is a variant of PCOS with hirsutism, insulin resistance,
acanthosis nigricans, and androgenization; these patients can also develop
impaired glucose metabolism and hyperlipidemia (1,3,9,94).

PCOS management
Table 29 lists management options for adolescents with PCOS (95-100).
If hirsutism is nor noted and the adolescent female is not sexually active
needing contraception, 10 mg of medroxyprogesterone (Provera) can be
prescribed for 12-14 days each month, to induce withdrawal bleeding.
Oral contraceptives (estrogen-dominant) can also be used in combination
with an antiandrogen medication (as spironolactone or cimetidine) to
reduce clinical signs of androgen excess (as hirsutism or acne if present),
and allow more clinically normal menstrual periods (1,6). The regular
use of contraceptive steroids (pill or patch) provides management of the
anovulation and unopposed estrogen stimulation of the endometrium
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found in patients with PCOS. Hormonal contraceptives can also suppress
hyperandrogenism and increase the production of sex steroid binding
globulin, thus helping prevent more hirsutism development.
Table 29. Management options for PCOS patients
Oral progesterone
Oral contraceptives (also transdermal ortransvaginal hormonal
contraceptives)
Spironolactone (androgen receptor antagonist)
Flutamide (androgen receptor antagonist)
Metformin
Electrolysis andthermolysis for hair removal
Obesity management
Acne vulgaris management
Ovulation induction (not often used inadolescents)
-Clomiphene citrate
-GnRH agonistic analogs (leuprolide acetate or nafarelin)
-Ovarian wedge resection.
Laser "drilling" of the ovary (decrease ovarian stromal steroids by
reducing the amount of stroma)
Management of additional endocrinopathies
Hirsutism is also managed with androgen receptor antagonists as
spironolactone (50-100 mg twice daily) or flutamide, another
antiandrogen medication that inhibits androgen uptake (1,6,101-104).
Other anti-androgen agents have been used, such as cyproterone acetate
(Cyprostat). Metformin (Glucophage) reduces serum insulin levels,
decreases ovarian cytochrome P450-17-α-hydroxylase activity, and
improves hyperandrogenism in obese PCOS patients (98,99). Other
medications used with type 2 diabetes mellitus have been used as well,
including pioglitazone (Actos) and rosiglitazone (Avandia). Future
sequelae of adolescent PCOS may include infertility, endometrial
carcinoma, diabetes mellitus (type 2), hyperlipidemia, and cardiovascular
disease (1,9). However, early intervention with alteration of dietary
habits, physical exercise, and androgen suppression therapy can
minimize adult morbidity. Diet intervention is considered most important
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as fresh vegetables, fruit and high fiber nutrition can reduce weight, as
well as metabolic consequences of PCOS.

AMENORRHEA IN ADOLESCENT ATHLETES
Irregular menstruation (i.e, amenorrhea and oligomenorrhea) is often
seen in females with strenuous exercise patterns. involving 10%-15% of
female athletes overall and two-thirds of the top female athletes (105111). Primary amenorrhea can also be seen as well, with a five month
menarche delay noted for each year of strenuous exercise in the prepubertal period (112). Secondary amenorrhea is well-known in females
engaged in such sports as ballet, cycling, gymnastics, and distance
running (108). Irregular menses is described in 12% of swimmers and
cyclists, 20% of females involved in excessive exercise in general, 44% of
ballet dancers, and 51& of endurance runners (108).
As noted in table 25 there are many factors that influence menstrual
cycles. Low body fat is not the only cause of menstrual irregularity and
former statements that menses cannot occur below a body fat percentage
of 17% have not been proven. A female athlete with amenorrhea can be
at the same body fat level as one with regular menses (109). A major
cause of lack of menstrual periods in athletes involved in excessive
exercise patterns is the resultant hypothalamic amenorrhea or
oligomenorrhea induced by dysfunction of GnRH productioi1 and LH
pulsitivity (108).
The strenuous exercise pattern of these athletes leads to a significant
drain of energy that their relatively low caloric intake cannot correct, in
order to sustain normal menses (109). Other factors may be involved as
well. such as stress, positive family history of irregular menses, chronic
illness, and others. A thorough search for other factors influencing
menses is important, before concluding that the athlete's menstrual
dysfunction is mainly due to intense exercise patterns. As noted before,
the investigation should include congenital anomalies, short stature,
hypoestrogenemia (see table 30), galactorrhea, virilization, and others
(1,108-110,113).
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Table 30. Methods to evaluate hypoestrogenemia in adolescents
Physical andsex development (delay of sex development)
Vaginal maturation index (VMI)
Vaginal smear toevaluate for epithelial cell estrogenization
Scrum estradiol level
Body weight
Bone mineral densitometry
The combination of amenorrhea, dysfunctional eating patterns, and
osteopenia or osteoporosis seen in some female athletes, has been termed
the Female Athlete Triad by the American College of Sports Medicine
(113). Various combinations of these three components can be seen in
female athletes, especially those whose sport emphasizes a thin or even
pre-pubertal physique that can be threatened by the normal changes of
puberty. The need for thinness can lead to unhealthy intake of calories,
protein, fat, and calcium. Young adolescents may develop delayed puberty
with their continued prepubertal (hypoestrogenic) state, while
postpubertal athletes can have chronic anovulatory amenorrhea and
oligomenorrhea with hypoestrogenism (109,110). The low estrogen
levels can prevent the development of normal peak bone mass with
increased risks for os1eopenia, osteoporosis, and stress fractures.

MANAGEMENT: FEMALE ATHLETE TRIAD
Management of the adolescent female· athlete with amenorrhea or
oligomenorrhea is based on the underlying etiology of the irregular
menses. If strenuous physical activity is a paramount factor, reducing the
exercise pattern by 10% or more and improving nutritional intake (with
calcium supplementation) will be beneficial (108-111,114). The athlete
can be educated that she is at increased risk for bone complications (i.e.,
reduced bone mineral density, osteopenia, and osteoporosis) if the
menstrual problems are part of a state of chronic hypoestrogenemia
(115). She may never develop a normal bone mineral density (BMD), if a
state of chronic amenorrhea and low BMD occurs, even if later menses
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becomes regular (108). Those with low BMD, and athletic occupations
such as dancing. are at increased risk for stress fractures (108).
Adolescents with the female athlete triad (i.e., menstrual dysfunction
and/or abnormal eating patterns) should receive daily supplementation of
calcium (1000-1500 mg per day), Vitamin D (400-800 IU), vitamin B
complex. and viatamin E (100-200 IU) (108-111, 116). Research notes that
about 50% of the required bone mass is obtained during adolescence, and
it is recommended by many clinicians to provide estrogen
supplementation in the form of oral contraceptives or conjugated
estrogen for the purpose of seeking bone loss prevention (117, 118). The
American Academy of Pediatrics recommends avoidance of hormonal
management if she is within three years of menarche; however, oral
contraception (or other estrogen supplementation) is suggested if she is
three years after menarche and over 16 years of age while always seeking
to improve nutritional intake, provide calcium supplementation, and
recommend a reduction in exercise patterns (119).
Unfortunately, many athletes who are committed to their sport will
refuse to reduce exercise schedules or alter established dietary patterns
(120). It is also important to understand that using estrogen
supplementation is controversial and not proven to improve or even
protect BMD with or without weight gain (108,109,121). It is also not
possible to predict the outcome in a specific athlete with the female
athlete triad, in terms of the actual effects of chronic menstrual
dysfunction and potential hypoestrogenemia in a specific youth
(108,120,122). Taking estrogen supplementation does not correct the
underlying menstrual abnormality and once the estrogen is stopped, there
is often a resumption of the previous menstrual dysfunction. Estrogen
consumption can lead to a number of side effects, including nausea,
emesis, breast tenderness, breast congestion, increased risk for clot
potential, and others (52,62). Some research suggests that using oral
contraceptives with ethinyl estradiol under 50 mcg may not prevent
osteoporosis (123). In our clinics, however, we have an overall better
outcome when these patients use combined oral contraceptives without
placebo for an average of six months, compared to those who do not use
OCPs (Omar, unpublished observation 2009).
Females with the most reduced BMD are those who are thin and
inactive, though strenuous physical activity patterns that involve weight
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bearing can lead to high mechanical forces that neutralize the potential
reduced BMD effect seen with a thin physique (108,120). Research
showed that accretion of bone can be increased with weight-bearing
exercise, and in some athletes with amenorrhea that results in having
normal or even increased BMD; these athletes are gymnasts, runners, ice
skaters, and tennis players (108,120).

DYSMENORRHEA
Primary dysmenorrhea
General
The term, primary dysmenorrhea, is used to define pelvic pain that
occurs during menstruation in which there is no overt pelvic pathology;
secondary dysmenorrhea refers to pain during menstruation due to
specific pelvic abnormalities, such as endometriosis or pelvic
inflammatory disease (see next section) (1,6,9,124,125). The pain of
primary dysmenorrhea can be mild (does not affect normal activity and
requires only minimal analgesic help), moderate (some reduction in
regular activity and requires regular use of analgesics), and severe
(unable to carry out regular activities and analgesics are typically not
helpful). Severe pain is often associated with nausea and emesis.
Primary dysmenorrhea typically begins 6 to 12 months after
menarche, though it may not be noted until the third gynecologic year
after menarche. The pain usually lasts 1-3 days typically initiating with
the menstrual flow or up to several hours after menses begins; sometimes
it occurs several to 48 hours before the menstrual flow starts. Nearly twothirds of ovulating females have some menstrual discomfort for 1-3 days
of most ovulatory menses, with nearly half of them having mild pain,
one-third having moderate pain, and 14% reporting severe pain. Primary
dysmenorrhea is the most common medical cause of school or job
absence and its incidence rises from the early teenage years through
young adulthood and first pregnancy.
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Etiology
The pain of primary dysmenorrheal mensrrual cramps is due to the
pathophysiology of the post-ovulatory period in which there is a rise and
fall of progesterone that leads to t he release of prostaglandins causing a n
increase in uterine contractions and an irritation of endometrial nerve
endings (1,6,9). The endometrium produces prostaglandins (e.g., PGF2α)
and leukotrienes f rom arachidonic acid through cyclooxygcnase and
lipooxygenase pathways, respectively. Reduced secretion o f
progesterone by the corpus luteum because of ovulation leads to a
breakdown of lysosomes in endometrial cells, with a release of
phospholipase A2, which converts fatty acids (derived from cell
membranes) into arachidonic acid. PGF2α and leukotrienes ( e.g.,
leukotricne B4 (LTB4) and leukotriene C 4 [LTC4]) stimulate smooth
muscle contractions.
There is increased resting tone of the myometrium, heightened
contractions (frequency and amplitude, and increased dysrhythmic
contractions. Vasoconstriction induces ischemia of tissue as well as
sensitization of myometrial neuronal endings co various pain-inducing
chemicals. Those with primary dysmenorrhea have increased levels of
circulating prostaglandins during menstruation (compared to those
without such cramps). There may also be increased sensitivity to
circulatory prostaglandins and increased levels of vasopressin that can
lead to increased myometrial contractions and more pain.
The reaction of individual adolescents to menstrual cramps can vary
from some that are unable to continue regular activities, to others that
seem Jess affected. Also, menstrual cramps can worsen with
psychological factors, such as depression or anxiety. In addition,
dysmenorrhea may be aggravated by factors such as longer menstrual
flow, obesity, and the copper IUD. Decreased pain may be seen with
parity, regular exercise, oral contraceptives, non-steroidal antiinflammatory drugs (NSAIDs), and the progesterone IUD (1).
Symptomatology
There may be a constant ache with superimposed crampy or spasmodic
pain that is bilateral and symmetrical; the pain is localized to the lower
abdomen but can radiate to the lower back or anterior thighs. A variety of
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additional symptomatology may be seen, as noted in table 31. The
differential diagnosis includes secondary dysmenorrhea and pain due to
genitourinary tract infections (pelvic inflammatory disease),
inflammatory bowel disease, endometriosis, tumors (ovarian or uterine),
and pregnancy (particularly early spontaneous miscarriage). Figure 4
provides a plan for the evaluation and treatment of dysmenorrhea.
Table 31. Features associated with primary dysmenorrhea

Backache
Diarrhea
Dizziness
Fatigue
Flushing
General malaise
Headache
Inner thigh pain
Lightheadedness
Low abdominal pain
Muscle cramps
Nausea
Vomiting

Secondary dysmenorrhea.
Though most episodes of dysmenorrhea in adolescents represent primary
dysmenorrhea, secondary dysmenorrhea can also be seen. In this case,
there is an underlying organic etiology to the pain. Clues to this diagnosis
include that the pain begins at menarche or three or more years after
menarche; also, there may be pain that is not colicky or crampy, it may
be associated with dysfunctional uterine bleeding or changing menstrual
patterns, it is not easily relieved with medications or there is a history of
pelvic surgery. Table 32 lists causes of secondary dysmenorrhea that
should be considered (1,6,9). Note that a diagnosis of a "retroverted"
uterus is not a cause of secondary dysmenorrhea.
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History and Physical
Not sexually
Active

Sexually active

Examine external genetalia
(Urine Culture)

Pelvic examination
(STD screen, urine culture)
Consider OCs or patch & NSAIDs
(Treat infection if present)

Trial NSAIDs

Pelvic US or pelvic exam

Improvement

Trial of OCs or patch with NSAIDs for at least 6 months

Laparoscopy

Endometriosis

Normal pelvic
(Other organ system)

Laser surgery

Other pelvic pathology
(see Table 1)

Consider GnRH agonists for 6 months

Consider acyclic, continuous monophasis OCs

+· improvement
- lack of improvement
Used andadapted withpermission: Blythe MJ. Commonmenstrual problems of
adolescence. In: Braverman PK, Strasburger VC, eds. Office-based
adolescent health care. Ado lesc Med 1997;8(1): 107, figure 2 and Greydanus
DE, Patel DR, Pratt HD, eds Essential adolescent medicine. New York:
McGraw-Hill, 2006:595.
Figure 4. Evaluation and treatment for dysmenorrhea and endometriosis.
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Table 32. Causes of secondary dysmenorrhea
Adhesions secondary to pelvic inflammatory disease or pelvic surgery
Anatomical genital defects (obstructing mullerian defects)
Complete cervical stenosis (with secondary amenorrhea and subsequent
dysmenorrhea
Endometriosis
Inflammatory bowel disease
Ovarian cysts
Pelvic tumors (including uterine leiomyomata)
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Evaluation: Medical history
A careful history is important in evaluating an adolescent who presents
with what appears to be pelvic pain, seeking to distinguish primary from
secondary dysmenorrhea or other non-gynecological causes. Table 33
lists important points 10 consider in taking a medical history. Congenital
malformations (i.e., vaginal septum and other Müllerian obstructive
anomalies) may present with pain because of menstrual flow obstruction;
there is a history of primary amenorrhea with normal breast
development, cyclic dysmenorrhea, and/or hematocolpos. In this
situation, the pain is typically present with menarche and imaging studies
allow a precise diagnosis.
Ovarian cysts may or may not be palpable and typically lead to
lateralized adnexal tenderness. Fortunately, most ovarian cysts are
asymptomatic, unlikely to cause pain, and finding a cyst does not
necessarily implicate the cyst as causing the dysmenorrhea. Symptomatic
cysts are typically follicular with such symptoms as irregular menses,
urinary frequency, sensation of abdominal or pelvic heaviness, and
constipation. Complications include cyst rupture with intra-abdominal
bleeding and cyst torsion. Oral contraceptives may suppress the
development of ovarian cysts. Fortunately, uterine tumors arc uncommon
in adolescent females.
Worsening menstrual pain in an adolescent who is sexually active
may be caused by endometritis. The pain rs often worse during
menstruation but occurs through the menstrual cycle. Pelvic
inf1ammatory disease (PID)-induced menstrual pain may increase during
the first seven days of the menstrual cycle and less frequently worsen in
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the premenstrual period, with improvement described as the flow starts.
Other evidence of PID will confirm the diagnosis, such as cervical
motion tenderness, or uterine/adnexal tenderness and/or laboratory
evidence of cervical infection with Neisseria gonorrhoeae or Chlamydia
trachomatis (1,6,9,126).
Table 33. Medical history ina patient with dysmenorrhea
Age at menarche
Last time menstruation was regular (if at all)
Pain description: location, timing to menarche, menstrual flow, frequency
Severity of the pain: mild, moderate, severe (are activities disrupted?)
Do pain medications improve or relieve the pain?
Flow description (duration and quantity)
Association with systemic factors (Table 31)
Sexual history and use of any contraception
History of pregnancy (and its outcome)
History of sexually transmitted diseases
History of dyspareunia
History of other systemic disorders (i.e., gastrointestinal, genitourinary,
others)
History of surgical procedures
Family history of various gynecologic conditions (Table 32)
(dysmenorrhea, endometriosis, ovarian cysts, infertility, virilization,
cancer, others)

Pain associated with vaginal bleeding may be due to early pregnancy
complications, such as ectopic pregnancy or miscarriage. Painful vaginal
bleeding can also be due co gastrointestinal disorders, urologic disorders,
intra-abdominal abscess., lesions of the sacrum. and orthopedic infections
(involving the hips and other joints). These conditions cause acute or
recurrent lower abdominal or pelvic pain but not the cyclical pain of primary
dysmenorrhea.

Evaluation: Physical examination and laboratory testing
If the history suggests mild primary dysmenorrhea with no pain apart
from the menstrual periods in an adolescent who is not sexually active, a
pelvic examination is not necessary. A general examination can be done
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that includes an inspection of the external genitalia to rule out an
imperforate hymen. If she is sexually active or if the pain is or becomes
moderate or severe. a pelvic examination should be part of the physical
examination process.
Laboratory testing and imaging is not usually needed for those with
what appears to be mild to moderate primary dysmenorrhea that responds
to basic medical management (see next section). If she is sexually active,
the possibility of a sexually transmitted disease and pregnancy should be
ruled out. The history and general physical examination may point to a
non-gynecologic cause, such as gastrointestinal, urinary, others; in such
cases, appropriate testing should be done (i.e., complete blood count,
urinalysis, urine culture, stool for occult blood, others as appropriate).
Ultrasonography is useful to identify such conditions as a pelvic
mass, pelvic abscess, adnexal torsion, ovarian cysts, pregnancy, and
others. The pelvic CT can be helpful if the ultrasound is indeterminate,
while the pelvic MRI is more sensitive to identify Müllerian anomalies.
Laparoscopy is needed to identify endometriosis or pelvic adhesions.

PRIMARY DYSMENORRHEA MANAGEMENT: NSAIDS
The first line of medical treatment for primary dysmenorrhea is one of
the NSAIDs (nonsteroidal anti-inflammacory drugs). NSAIDs include
type I inhibitors (carboxylic acids) (sec table 34) and type II (enolic acids
that include pyrazolones [phenylbutazone] and oxicams [piroxicam])
(1,6,9,125). Enolic acids inhibit cyclic endoperoxidc cleavage enzymes
(reductase isomerase) after formation of cyclic endoperoxides as a later
step in prostaglandin production. Enolic acid medications are not as
effective as carboxylic acids (see table 33) ant have more side effects.
Thus, type I inhibitors (carboxyJic acids) are the main type of NSAIDs
used to manage primary dysmenorrhea.
Carboxylic acids suppress cyclic cndope1oxide synthetase at the
cyclooxygenase level and are effective medications to relieve the pain of
primary dysmenorrhea. However, aspirin has limited anti-inflammatory
effect on the endometrium and is not a potent reliever of menstrual
cramps. Indomethacin is more effective, but its many side effects limits
its use for treatment of primary dysmenorrhea; these adverse effects
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include gastrointestinal effects (i.e., ulceration, perforation, bleeding). renal
insufficiency, breast tenderness, headaches, vaginal bleeding, andothers.
Table 34. NSAIDs: Type 1 inhibitors: Carboxylic adds

1. Salicylic acid esters: aspirin
2. Acetic acids: indomethacin
3. Propionic acids: ibuprofen, naproxen, naproxen sodium, and
ketoprofen
4. Fenamic acids: mefenamic acid, meclofenamate
Thus, propionic acids (i.e., ibuprofen, naproxen sodium, others) have
been used because of effective relief of pain with less toxicity than the
other mentioned medications; they are FDA-approved for treatment of
primary dysmenorrhea. Side effects include gastrointestinal effects and
headaches. Propionic acids (see table 34) are available as over-thecounter medications. Naproxen sodium bas a long half-life allowing a
twice-a-day dosing. Ketoprofen inhibits prostaglandin and leukotriene
synthesis, stabilizes lysosomal membranes, and has anti-bradykinin
action. Dosages for propionic acids are noted in table 35. Fenamic acids
have a rapid onset of action, block myometrial receptor sites for
prostaglandins that have been synthesized, inhibit 5-lipooxygenase
activity (that can suppress production of leukotrienes), and can reduce
heavy flow of menses. Table 35 lists basic dosage of mefenamic acid.
An NSAID (as ibuprofen, naproxen sodium, naproxen, others) is
started at the onset of the menstrual flow or even before the anticipated
flow onset, especially if pain precedes the bleeding. Sta,ting the medication
before the flow starts is also helpful if emesis is part of the
menstrual cycle. The medication is continued for 2-4 days, depending on
how long the pain usually lasts. Improvement of the pain and even the
amount of blood loss is noted (see section on DUB). If a propionic acid is
not beneficial after a few months trial. the adolescent female can try a
fenamic acid for a few more months' trial. Overall efficacy in partial or
full relief of pain is as high as 80%. Failure of improvement may be due
to the lack of prostaglandin synthetase inhibitors blocking the 5-
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lipooxygenase pathway that allows continued production of leukotrienes
and continued dysmenorrhea.
Table 35. NSAIDs for the treatment of primary dysmenorrhea

Drug

Initial Dose

Ibuprofena

400
25-50
550

(mg)

Ketoprofena

Naproxena
sodium

500
500

Maintenance
Dose

400 mg q4h
25-50 mg q6-8h
275 mg q6-8h or
550 mg q12h
250 mg q6-8h
250 mg q6h

Maximum
Dose/24 hours
(mg)

3200
300
1375
1250
Not established

Naproxen
Mefenamic acid
a Available as over-the-counter drugs (ibuprofen; 200 mg tablets; ketoprofen:
12.5 mg tablets; naproxen sodium: 220 mg tablets).

PRIMARY DYSMENORRHEA MANAGEMENT:
O RAL CONTRACEPTIVES
Oral contraceptives are also used for primary dysmenorrhea if NSAIDs
are not effective and may be the first line of treatment for sexually active
youth with dysmenorrhea (1,6,9,125). Oral contraceptives prevent
ovulation that in turn prevents the post-ovulatory high prostaglandin
levels due to a corpus luteum. The lack of such high progesterone levels
prevent an important step in prostaglandin production and thus, lack of
overt painful menstrual cramps. Added benefits include effective
contraception and less menstrual flow (see DUB section). An efficacy
rate of 90 to 95% can be seen with the use of oral contraceptives in the
management of primary dysmenorrhea. Similar results can be achieved
with use of other hormonal contraceptives such as: transdermal,
transvaginal, injectible, or implantable (subdermal) methods. A
combination of hormonal contraceptives and NSAIDs can also be
effective. If the use of NSAIDs and/or oral contraceptives is not
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effective, the possibility of secondary dysmenorrhea should be reconsidered.

PRIMARY DYSMENORRHEA MANAGEMENT: OTHERS
A variety of other measures may be useful in managing primary
dysmenorrhea, including use of a menstrual calendar to get a clear
picture of menstrual timing, reduction of sugar as well as caffeine,
encouragement of adequate rest as well as regular exercise, and reduction
of excess stress ( 1,6,9). Psychological factors (as depression and anxiety)
can worsen pain from various causes. Fish consumption containing
omega-6 fatty acids (e.g., salmon) can help minimize menstrual cramps.
Unproven options with anecdotal testimonies of success in some adult
patients include calcium channel blockers (i.e., nifedipine), acupuncture,
and cranscutaneous electrical nerve stimulation (TENS). Side effects of
nifedipine include headaches and hypotension. Education of the
adolescent female about dysmenorrhea and its treatment options is
important (127).
Table 36. Premenstrual syndrome ( PMS) symptomatology
Emotional Features
Anecdotal reports of violence and suicide
Anger
Anxiety
Concentration difficulties
Crying
Decreased libido
Depression
Feelings of being out of control or overwhelmed
Lethargy
Mood swings
Withdrawal from usual activities
Physical Features
Acne
Anorexia
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Bloating
Breast tenderness or swelling
Constipation
Diarrhea
Edema
f
Facial puf iness
Fatigue
Headache
Increased appetite
Lower abdominal or pelvic pain
Pain: joints or muscles
Swelling of hand
Swelling of feet
Weight gain

PREMENSTRUAL SYNDROME
Premenstrual syndrome (PMS) refers to a variety of symptoms that begin
during the last part of the luteal menstrual cycle, just prior to the
menstrual flow, and resolve with the onset of menstruation so that they are
absent the week after menses starts (1,6,9,128,129). PMS may begin
several days to two weeks prior to menses and the symptoms can be
divided into emotional and physical features (see table 36); patients
report various combinations of these features. Most females of
reproductive age will note some PMS symptoms, while 3% to 8% report
severe enough emotional features (i.e, depression, anxiety, inability to
perform daily tasks) that the condition meets criteria for Premenstrual
Dysphoric Disorder (PMDD) as defined by the American Psychiatric
Association's (APA) Diagnostic and Statistical. Manual of Mental
Disorders (1994, 2000) (130-132). Patients with PMDD have five or
more of these APA criteria (i.e., sadness, loss of self-worth, mood
lability, anxiety, withdrawal from social relationships, anger, persistent
irritability, others) in the luteal menstrual phase for at least one year.
PMS should be identified as a separate category from dysmenorrhea.
Pelvic pain is not a symptom of PMS, unless other disorders are present,
such as endometriosis. PMS may be confused with other disorders
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including hypothyroidism, chronic fatigue syndrome, collagen vascular
disorder, anemia, diabetes mellitus, and others (1,6,9). A number of
conditions can be worsened by menstruation and can add to the
differential diagnostic confusion (see table 37).
Table 37. Conditions worsened by menstruation
Acute intermittent porphyria
Erythema multiforme
Migraine headaches
Periodic fever
Periodic hypersomnia
Periodic paralysis
Recurrent anaphylaxis
Rheumatoid arthritis

PMS etiology
Though the precise etiology is not known, etiologic theories often center
on dysfunction of serotonin or γ -aminobutyric acid A (GABA-A)
(1,6,9). For example, one theory implicates heightened sensitivity to
hydroxy-tryptamine (5-HT) receptors with reduced levels and impaired
uptake of serotonin. Some research has concluded that anxiety can be
enchanced by dysfunctional interaction of metabolites of progesterone and
receptors of γ-aminobutyric acid A (GABA-A) receptors. Other
research notes that increasing late luteal phase levels of PCO2 can induce
reduced threshold for a panic attack, Recurrent episodes of PMS may lead
to increased sensitization to these mechanisms and more PMS
symptomatology. Current research implicates a corn pl ex interaction
between prostaglandins, central neurotransmitters (as serotonin),
endogenous opioid peptides, peripheral autonomic nervous system, and
ovarian steroids. Psychological issues may be worsened by PMS
symptoms but are not primarily causative of PMS.

Menstrual Disorders in Adolescent Females

391

PMS management
General measures often recommended for youth with PMS include
adequate re-st. exercise. regular hot baths, reduced intake of caffeine as
well as sugar, reduced salt intake, avoidance of alcohol, and reduction in
factors causing excessive stress (1,6,9). If depression or anxiety is noted,
psychological management may be helpful (133). Beneficial effects on
the emotional features of PMS bas been seen by using selective serotonin
reuptake inhibitors (SSRIs) such as fluoxetine (20 mg daily), sertraline
(50 mg daily), or paroxetine (20 mg daily) (1,6,9,128,134,135). The
United Stares FDA has placed a "black box" warning on SSRis due to
increased suicidal ideation and behavior noted in children and
adolescents taking SSRIs (136). Patients with anxiety may benefit from
the use of anxiolytics (alprazolam or buspirone). Tricyclic
antidepressants have been helpful as well, including clomipramine (136).
Though not recommended for adolescents, adult females with severe
PMS have reported improvement with gonadotropin-releasing hormone
(GnRH) agonists (such as leuprolide [Lupron] and buserelin (Suprefact])
that induce a medical oophorectomy by suppressing gonadotropin release
with resultant suppression of ovulation and ovarian hormone synthesis.
NSAIDs (such as ibuprofen) may be helpful probably by improving
breast and/or pelvic pain. Diuretics (such as hydrochlorothiazide or
spironolactone) may be beneficial in some by improving PMS edema or
weight gain; however, abuse of diuretics may lead to increased edema.
Bromocriptine is a dopamine-receptor agonist that has been used in adult
females to relieve severe mastalgia seen in some with PMS. Measures
attempted, but without specific research to verify benefit, include oral
contraceptives. progesterone. thyroid hormone supplementation, lithium,
evening primrose oil, atenolol, prostaglandin inhibitors, vitamin E or B6
supplementation, and supplementation with calcium or magnesium
(1,6,9,137).
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PELVIC PAIN

Mittelschmerz
This refers to pain in the lower abdominal quadrants that occurs in the
middle of the menstrual cycle in association with ovulation (1,9,138).
The cause of the pain is probably the result of pelvic irritation induced by
contents of the discharged (dominant) ovarian follicle. Mittelschmerz
(German: middle pain) does not occur in anovulation. The pain or
discomfort is usually unilateral, crampy, lateralized, lasts from several
hours to four days, and typically changes sides from month to month. It
may be accompanied by mild bleeding or vaginal secretion changes.
Fortunately Mittelschmerz is rarely severe and sometimes can be
confused with an ovarian cyst, ovarian torsion, ectopic pregnancy or
appendicitis. Management includes education of its cause, reassurance,
analgesics, and ifsevere, ovulation inhibition with oral contraceptives.

Endometriosis
Endometriosis involves the development of functional endometrial tissue
(i.e., stroma and glands) outside the uterus (1,6,139-141). Though it
mainly presents in adult females in the third and fourth decade of life,
it may be seen in adolescent females as well; it has been reported as young
as 101/2 years of age. Incidence of 10%-17% has been reported in adult
females and 40%-65% or more of adolescents with chronic pelvic pain
(including secondary dysmenorrhea) may have endometriosis as noted on
laparoscopy (1,140-142).

Etiology

Endometrial tissue can be refluxed from the oviducts during
menstruation in a condition termed retrograde menstruation or
endometrial tissue may develop from many small cysts found on various
structures: ovaries, surface of the uterus, pelvic ligaments or the
peritoneum (coelomic metaplasia). Etiologic theories include genetic
factors, lymphatic-vascular metastases, and immunologic deficiencies in
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which cell-mediated defects lead to endometrial cells that are not cleared
from non-uterine structures (1,139-143). Endometriosis can be found in
7% of close relatives of a patient with this condition, in contrast to 1% of
controls (1). The pain of endomeniosis develops when endometrial cysts
enlarge or swell during the menstrual cycle; pain can also occur because
ofpelvic adhesions or because nerve endings are stimulated.
Symptomatology
Classic features of endometriosis incude severe dysmenorrhea, pelvic
mass, and infertility (140-143). Symptoms can be similar in adolescents
versus adult females, though adolescents are more likely to have
congenital reproductive tract anomalies (such as imperforate hymen,
anomalies,
uterine
hematometra,
transve.rse
septum,
vaginal
The
hematocolpos) and renal agenesis (144).
dysmenorrhea may be
localized to the lower abdomen, groin, thigh, back, or deep in the pelvic.
The pain can be worsened by coitus, improved with rest, and may
become cyclical, acyclical, aud chronic. There is no correlation between
the intensity of tbe pain and the extent of endoroetriosis (i.e., the number
of endometriotic lesions does not correlate with the severity of the pain).
There may be abnormal menstrnal bleeding (including bleeding
before menses), dysuria, clinical hematuria, suprapubic pain, and
dyspareunia. There may be primary amenorrhea with normal sexual
development; in otl1ers there is dysfunctional uterine bleeding or
persistent pain worse.ning with meostTuation. Bowel symptomatology
may occur especially in the late luteal and menstrual phases; these
symptoms include rectal pressure, urgency, and pain with defecation
(dyschezia). The symptoms can be modified by complica1ions including
adhesions, mass effects, internal bleeding, or even changes in bowel or
bladder functions. Endometriosis can present as an adnexal mass, large
ovarian endometriornas, or with diffuse disease.
Diagnosis
The correct diagnosis of endometriosis begins with a careful history as
reviewed under Symptomatology above. The pelvic eitaminatiou may be
normal or, especially if performed during the late Juteal phase of the
menstrual cycle, may reveal pelvic tenderness, thick broad ligaments,
immobile
(fixed) uterus, or variable nodularity with or without
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tenderness (see table 38). Ultrasonography may reveal various cysts
scattered in the pelvis or may reveal an adnexal mass, while a pelvic
l'\IIRI is the best procedure to identify genital reproductive tract anomalies
and a hysterosalpingography can be useful as well. CA-125 (cell surface
antigen) can be increased in patients with endometriosis and though
it has a low sensitivity (i.e., is not a good screening test), serum levels of
CA-125 have been used to follow patient response to management (1).
Laparoscopy with biopsy is the confirmatory test for endometriosis
and is recommended for females with chronic pelvic pain of unknown
cause that does not improve with NSAIDs and oral contraceptives
(1,6,140-146). Endometrial lesions in youth may have a different
appearance than in adult females and the examiner must be familiar with
lesions found in adolescents (140,143). Early lesions of endometriosis
are pigmented, pale, cystic, vesicular, or hemorrhagic; more typical adult
lesions reveal areas characterized with retraction, fibrosis, "powder burn"
lesions or overt endometriomas that can be very small or several
centimeters in diameter.

DIFFERENTIAL DIAGNOSIS OF CHRONIC PELVIC PAIN
Tables 22, 38-40 list causes of acute and chronic pelvic pain in
adolescent and adult females (147,148). Consultation is often necessary
with experts in gynecology, surgery, urology, and others (1,6,9,147,148).
A thorough history and physical examination is important to identify the
specific cause along with various laboratory testing that includes
complete blood count, urinalysis (with urine culture), pregnancy testing,
and STD te-sting (Chlamydia trachomatis, Neisseria gonorrhoeae, others)
(126,149). Pelvic ultrasonography and diagnostic laparoscopy are often
important aids in identifying a specific etiology. Laparoscopic results in
patients with acute pelvic pain include a normal pelvis in 30%. ovarian
cysts in 40%, pelvic inflammatory disease in 30%, appendicitis in 10%,
adnexal torsion in 5%, ectopic pregnancy in 3% (150). Laparoscopic
findings in patients with chronic pelvic pain of 3 months duration or
more include endometriosis in 45%, a normal pelvis in up to 40%, pelvic
inflammatory disease in up to 15%, postoperative adhesions in up to
13%, uterine anomalies in 5% to 8%, and ovarian cysts in 5% (150).

Table 38. Differential diagnosis approach to pelvic pain*

Characteristics of pain
MIDLINE LOCATION
Cyclical, normal bleeding

Likely diagnosis

Confirmatory investigations

Primary dysmenorrhea

History; pelvic examination (normal)
Pelvic examination; sonography;
laparoscopy
Pelvic examination, cultures; CBC;
sedimentation rate
History; pelvic examination;
pregnancy rest
History; urinalysis, urine culture
History; pregnancy test

Endometriosis
Acute, irregular bleeding

Endometritis
Threatened or septic abortion

Unrelated to menses, urinary
symptoms*
LATERAL LOCATION
Cyclical, normal bleeding

Cystitis
Normal uterine pregnancy

Mittelschmerz
Endometriosis

Acute, postmenstrual

Salpingitis or pelvic inflammatory
disease

History (timing, nature); pelvic
examination (normal)
Pelvic examination; sonography;
laparoscopy
Histocy; pelvic examination., cultures;
CBC, sed rate; laparoscopy
History; pelvic examination,
pregnancy test

.Acute abnormal bleeding

Ectopic pregnancy

Unrelated to menses, acute

Apendicitis
Ureteral colic

Unrelated to menses. chronic

Constipation
Pelvic osteomyelitis

History; physical examination; CBC:
radiography
History; urinalysis; radiography
History: rectal examination
Physical examination; radiography:
gallium scan
History; exclusion of others;
psychosocial evaluation

Psychogenic
Abbreviation: CBC= complete blood count.
aDysuria and urinary frequency may be associated with infection, pregnancy, and psychogenic factors.

Reprinted, with permission, from: Greydanus DE. Breast and gynecological disorders. In: Hofmtum AD. Greydanus DE, eds.
Adolescent medicine, 3rd ed. Stamford, CT: Appleton I.ange, 1997:547.

·Table 39. Causes of chronic pelvic pain in women
• GYNECOLOOICAL
Noncyclical

Adhesions

Endomettiosis
Salpingo-oophoritis
Acute
Subacute
Ovarian remnant syndrome
Pelvic congestion syndrome
Ovarian neoplasms
Pelvic relaxation
• CYCLICAL

Primary dysmenorrhea

Secondaiy dysmenorrhea
·Imperforate hymen
Transverse vaginal septum
Cervical stenosis
Uterine anomalies
(congenital malformation, bicornuate
uterus, blind uterine horn)
Intrauterine synechiae (Asherman's

• CYCLICAL
Atypical cyclical
Endometriosis
Adenomyosis
Ovarian remnant syndrome
Chronic functional cyst formation
• GASTROINTESTINAL
Irritable bowel syndrome
Ulcerative colitis
Granulolmatous colitis (Crohn's
disease)
Carcinoma
Infectious diarrhea
Recurrent partial small bowel
obstruction
Diverticulitis
Hernia
Abdominal angina
Recurrent appendiceal colic
• GENITOURINARY

• NEUROLOGICAL
Nerve entrapment syndrome
Neuroma
• MUSCULOSKELETAL
Low back pain syndrome
Congenital anomalies
Scoliosis and kyphosis
Spondylolysis
Spinal injuries
Inflammation

Tumors

Osteoporosis
Degenerative changes

Coccydynia

Myofascial syndrome
• SYSTEMIC
Acute intermittent porphyria
Abdominal migraine
Systemic lupus erythematosus

Recurrent or relapsing
Lymphoma
Neurofibromatosis
cystourethritis
Urethral syndrome
Interstitial cystitis
Ureteral diverticuli or polyps
Carcinoma of the bladder
Ureteral obstruction
Pelvic Kidney
Source: Reprinted with permission, from Rapkin AJ, Reading AE: Chronic pelvic pain. Curr Probl Obstet Gynecol Fertil 199;
14:101.
syndrome)
Endometrial polyps
Uterine leiomyoma
Adenomyosis
Pelvic congestion syndrome
Endometriosis
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Management
Table 41 and figure 4 list treatment options for endometriosis which is a
chronic condition of variable severity that requires consultation wich
gynecologic consultants (151). NSAIDs are not usually helpful in
relieving the pain of endometrosis. Reduction and even disappearance of
endometrial tissue outside of the uterus may occur with the use of oral
contraceptives (OCPs), transdermal or transvaginal hormonal
contraceptives or medroxyprogesterone acetate (Provera [30-50 mg
orally once a day] or Depo-Provera [150 mg intramuscularly once a
month or every 3 months]) (1,6.143). Side effects of progestins include
weight gain, irregular bleeding, depression, bloating, and others. A
progestin-dominant oral contraceptive may be helpful in some.
Another treatment option is methyltestosterone (5-10mg bucally
each day) since androgens inhibit endometrial growth. Side effects of
androgens include virilization of the female and teratogenic potential
(masculinization of a female fetus). Gonadotropin-releasing hormone
agonises (leuprolide acetate or nafarelin acetate) are also used alone or in
combination with estrogen because these agonists induce a state of
menopause that is reversible leading to absence of menses, vaginal
dryness, hot flashes, and bone loss. These agonises are typically
withdrawn after 6 months, though adding estrogen may allow longer
agonise use. Danocrine (Danazol) is a l 7a-ethinyl-testosterone derivative
and is also used; it is prescribed at 400 mg twice a day orally, leading to
improvement of pain in 90% (143). Adverse effects include weight gain,
edema, abnormal liver function tests, fetal androgenization, acne, lipid
dysfunction, and ochers. Anastrozole is a drug (aromatase inhibitor) used
to treat breast cancer that has been used in adult women with
endometriosis along with oral contraceptives to treat endometriosis
(152).

Table 40. Differential diagnosis of pelvic masses
Characteiistic of Mass

Differential Diagnosis

Confirmatory History,
Findings, and Procedure

MIDLINE LOCATION
With amenorrhea or abnormal
menses

Pregnancy

History of sexual activity; positive pelvic
examination
History of no menses, cyclic pelvic pain; perineal
examination reveals imperforate hymen, vaginal
stenos is
Negative pregnancy test; uterine enlargement;
sonography CT; tissue diagnosis
History of acute retention; findings of herpetic or
other lesions precipitating retention; catheterization

Hematocolpos, hematometra
Uterine sarcoma (rare)

With normal menses

LATERAL LOCATION With
amenorrhea or abnormal
menses

Bladder

Functioning ovarian cyst
Ovarian tumor

Polycystic ovary syndrome

History of menstrual irregularity; negative
pregnancy test; unilateral mass; physical or
laboratory evidence of hormonal abnormalities;
sonography, laparoscopy, tissue diagnosis
As above with bilateral ovarian enlargement
History of sexual activity; pregnancy test may or
may not be positive; sonography; may or may not

Ectopic pregnancy

With normal menses

Tuboovarian abscess
Nonfunctioning ovarian cyst
Appendiceal abscess

have pain or tenderness; may present as acute
emergency
History and findings compatible with pelvic
inflammatory disease; sonography, laparoscopy
History of pain or asymptomatic; unilateral mass; may
be very large; sonography, laparoscopy, tissue
diagnosis
History of appendicitis (or acute abdominal
condition); positive rectal or abdominal
examination; may be difficult to distinguish from
pelvic inflammatory disease; sonography,
laparotomy
History of constipation; positive rectal or
abdominal examination; abdominal
roentgenograms

Fecal impaction
Abbreviation: C T = computed tomography
Reprinted, with permission, from: Gre,danus DE: Breast and gynecological disorders. In: Hofmann AD, Greydanus DE, eds.
Adolescent medicine, 3rd ed. Stamford, CT: Appleton Lange, 1997:559.
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Surgical management options are noted in
table 41
(1,6,140,141,143,145,150-155). Hormonal treatment can be provided
after surgery because endometriosis often continue after surgical
treatment. Correction of congenital anomalies that may be present is also
important, as for example correction of an imperforate hymen, a
transverse vaginal septum or excision of a rudimentary blind horn.
Surgery should seek to preserve fertility if possible.
Table 41. Treatment options for endometriosis
Oral contraceptives
Medroxyprogesterone acetate (Provera or Decpo-Provcra)
Androgens (methyltestosterone)
Gonadotropin-releasing hormone agonists (leuprolide acelate or nafarelin
acetate)
Danazol (danocrine)
Anastrozole (Arimidex)
Laparoscopic ablation
LUNA (Lase, Uterosacral Nerve Ablation)
Electrocautcry
Thermocoagulalion
Laparotomy with resection of endometriomas
Presacral neurectomy
Correction of associated congenital reproductive anomalies
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